



(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 31/20 (2006.01)  
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2019/046142

(22) International Filing Date:

12 August 2019 (12.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/718,314 13 August 2018 (13.08.2018) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: JADHAV, Vasant R.; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). MAIER, Martin A.; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). MILSTEIN, Stuart; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). SCHLEGEL, Mark K.; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: SARGEANT, Brooke et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF




Fig. 2A




Fig. 2B

(57) Abstract: The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, e.g., chronic hepatitis B infection.



WO 2020/036862 A1

**Declarations under Rule 4.17:**

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

## HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

### STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format  
5 in lieu of a paper copy, and is hereby incorporated by reference into the specification.  
The name of the text file containing the Sequence Listing is  
930385\_410WO\_SEQUENCE\_LISTING.txt. The text file is 83.1 KB, was created on  
August 4, 2019 and is being submitted electronically via EFS-Web.

### BACKGROUND

10 Worldwide more than 400 million people are chronically infected with HBV  
and are, thus, at increased risk of developing serious liver disease, such as chronic  
hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC) resulting in an  
estimated 600,000 deaths each year.

The natural evolution of chronic HBV infection includes four consecutive  
15 phases: (1) early ‘immunotolerant’ phase, high levels of virus replication and minimal  
liver inflammation; (2) immune reactive phase, significant hepatic inflammation and  
elevated serum aminotransferases; with some patients progressing to (3) ‘non-  
replicative’ phase, seroconversion to anti-HBe, undetectable or low level of viremia  
(below 2000 IU/ml by PCR-based assays), and resolution of hepatic inflammation; and  
20 (4) HBeAg-negative chronic hepatitis B, due to the emergence of specific viral  
mutations, which prevent the production of HBeAg but do not hamper virus replication.  
This form of chronic hepatitis B (CHB) is characterized by fluctuating serum HBV  
DNA and serum aminotransferases (ALT and AST) levels and progressive liver disease.  
It is important to note that CHB may present either as HBeAg-positive or HBeAg-  
25 negative CHB. Longitudinal studies of patients with CHB indicate that the 5-year  
cumulative incidence of developing cirrhosis ranges from 8 to 20%. The 5-year  
cumulative incidence of hepatic decompensation is approximately 20%. The  
worldwide incidence of HCC has increased and presently constitutes the fifth most  
common cancer. The annual incidence of HBV-related HCC is high, ranging from 2-  
30 5% when cirrhosis is established.

The primary goal of treatment for HBV is to permanently suppress HBV  
replication and improve liver disease. Clinically important short-term goals are to  
achieve HBeAg- seroconversion, normalization of serum ALT and AST, resolution of  
liver inflammation, and prevention of hepatic decompensation. The ultimate goal of

treatment is to achieve durable response to prevent development of cirrhosis and liver cancer to prolong survival. HBV infection cannot be eradicated completely due to persistence of a particular form of viral covalently closed circular DNA (cccHBV DNA) in the nuclei of infected hepatocytes. However, treatment-induced clearance of serum HBsAg is a marker of termination of chronic HBV infection and has been associated with the best long-term outcome.

The current standard methods of treatment for HBV include interferon- or thymosin  $\alpha$ 1 -based immunotherapies and the suppression of viral production by inhibition of the HBV polymerase. HBV polymerase inhibitors are effective in reducing viral production but have little to no effect in rapidly reducing HBsAg or can slowly reduce HBsAg with long term treatment in a limited number of patients (as is the case with tenofovir disoproxil fumarate). Interferon-based immunotherapy can achieve a reduction of both viral production and early removal of HBsAg from the blood, but only in a small percentage of treated subjects. The generally accepted role of HBsAg in the blood is to sequester anti-HBsAg antibodies and allow infectious viral particles to escape immune detection, which is likely one of the reasons why HBV infection remains a chronic condition. In addition HBsAg, HBeAg, and HBcAg all have immuno-inhibitory properties and the persistence of these viral proteins in the blood of patients following the administration of any of the currently available treatments for HBV is likely having a significant impact in preventing patients from achieving immunological control of their HBV infection.

Although the three primary HBV proteins (HBsAg, HBeAg, and HBcAg) all have immunoinhibitory properties, HBsAg comprises the overwhelming majority of HBV protein in the circulation of HBV infected subjects. Additionally, while the removal (*via* seroconversion) of HBeAg or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and seroconversion) in HBV infection is a well-recognized prognostic indicator of antiviral response on treatment that will lead to control of HBV infection off treatment (although this only occurs in a small fraction of patients receiving immunotherapy). Thus, while reduction of all three major HBV proteins (HBsAg, HBeAg, and HBcAg) may result in the optimal removal of inhibitory effect, the removal of HBsAg alone is likely sufficient in and of itself to remove the bulk of the viral inhibition of immune function in subjects with HBV infection.

Therefore, in the absence of any current treatment regimen that can restore immunological control of HBV in a large proportion of patients, there is a need for an effective treatment against HBV infection that can inhibit viral replication as well as

restore immunological control in the majority of patients. Accordingly, there is a need in the art for alternative therapies and combination therapies for subjects infected with HBV or having an HBV-associated disease.

#### SUMMARY OF THE INVENTION

- 5           In some embodiments, the present disclosure provides double stranded ribonucleic acid (dsRNA) agent compositions that affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a Hepatitis B virus (HBV) gene. The HBV gene may be within a cell, *e.g.*, a cell within a subject, such as a human.
- 10           The present disclosure also provides methods and therapies for treating a subject having a disorder that would benefit from inhibiting expression of an HBV gene, *e.g.*, an HBV infection or an HBV-associated disease, such as chronic Hepatitis B infection (CHB), using dsRNA agent compositions that affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an HBV gene for inhibiting
- 15           the expression of an HBV gene.

In one aspect, the present disclosure provides dsRNA agents for inhibiting expression of HBV. For example, the present disclosure provides a dsRNA agent comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises the modified nucleotide sequence as set forth in:

- 20           5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16),  
               5'-usGfsuga(Agn)gcgaaguGfdCAfcacsusu-3' (SEQ ID NO:18),  
               5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20),  
               5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23),  
               5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24),  
 25           5'-usGfsudGadAgdCGfaaguGfdCAfcacsusu-3' (SEQ ID NO:25), or  
               5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28),

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

- 30           Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate,

- 35           respectively;

(Agn) is adenosine-glycol nucleic acid (GNA); and  
s is a phosphorothioate linkage.

In some embodiments, the sense strand comprises the modified nucleotide  
sequence 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29),

5 wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-  
methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-  
methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-  
phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate,  
10 respectively; and

s is a phosphorothioate linkage.

In some embodiments, the antisense strand and the sense strand comprise the  
modified nucleotide sequences as set forth in:

(a) 5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16) and 5'-  
15 gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(b) 5'-usGfsuga(Agn)gcgaaguGfdCAfcacsusu-3' (SEQ ID NO:18) and 5'-  
gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(c) 5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20) and 5'-  
gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

20 (d) 5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23) and 5'-  
gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(e) 5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24) and 5'-  
gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(f) 5'-usGfsudGadAgdCGfaaguGfcAfdCacsusu-3' (SEQ ID NO:25) and 5'-  
25 gsusguGfcAfCfUfucgcuucaca -3' (SEQ ID NO:29); or

(g) 5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28) and 5'-  
gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

30 wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-  
methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-  
methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-  
phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate,  
respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-  
35 phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate,  
respectively;

(Agn) is adenosine-glycol nucleic acid (GNA); and  
 s is a phosphorothioate linkage.


In some embodiments, at least one strand of the dsRNA agent comprises a 3'  
 overhang of at least 1 nucleotide. In some embodiments, at least one strand of the  
 5 dsRNA agent comprises a 3' overhang of 2 nucleotides.

In some embodiments, the double stranded region of the dsRNA agent is 19-21  
 nucleotide pairs in length.

In some embodiments, each strand of the dsRNA agent independently has 19-23  
 nucleotides. In some embodiments, each strand of the dsRNA agent independently has  
 10 19-21 nucleotides.

In some embodiments, dsRNA agent further comprises a ligand. In some  
 embodiments, the ligand is conjugated to the 3' end of the sense strand of the dsRNA  
 agent. In some embodiments, the ligand is an N-acetylgalactosamine (GalNAc)  
 derivative. In certain embodiments, the ligand is

15



In some embodiments, the dsRNA agent is conjugated to the ligand as shown in  
 the following schematic



In some embodiments, the present disclosure provides a dsRNA agent, wherein the sense strand and the antisense strand consist of the modified nucleotide sequences as set forth in:

- (a) 5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);
- (b) 5'-usGfsuga(Agn)gCGaaguGfdCAfcacsusu-3' (SEQ ID NO:18) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);
- (c) 5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);
- (d) 5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23) and 5'-gsusguGfcAfCfUfucgcuucaca -3' (SEQ ID NO:29);
- (e) 5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24) and 5'-gsusguGfcAfCfUfucgcuucaca -3' (SEQ ID NO:29);
- (f) 5'-usGfsudGadAgdCGfaaguGfcAfdCacsusu-3' (SEQ ID NO:25) and 5'-gsusguGfcAfCfUfucgcuucaca -3' (SEQ ID NO:29); or
- (g) 5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA);

s is a phosphorothioate linkage; and

the 3' end of the sense strand is conjugated to an N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol (L96) ligand.

In another aspect, the present disclosure also provides a cell containing a dsRNA agent as disclosed herein.

The present disclosure also provides a pharmaceutical composition comprising a dsRNA agent described herein and a pharmaceutical excipient.

The present disclosure also provides a method of inhibiting Hepatitis B virus (HBV) gene expression in a cell, the method comprising contacting the cell with a

dsRNA agent or a pharmaceutical composition as disclosed herein, thereby inhibiting expression of the HBV gene in the cell. In some embodiments, the cell is within a subject. In some embodiments, the subject is a human. In some embodiments, the subject suffers from an HBV-associated disease. In some embodiments the cell is *in vitro*.  
5 *in vitro*. In some embodiments, the HBV gene expression is inhibited by at least 80%, 90%, 95%, or 98%, or to below the level of detection of the assay method.

The present disclosure also provides a method of inhibiting replication of a Hepatitis B virus (HBV) in a cell, the method comprising contacting the cell with a dsRNA agent or a pharmaceutical composition as disclosed herein, thereby inhibiting  
10 replication of the HBV in the cell. In some embodiments, the cell is within a subject. In some embodiments, the subject is a human. In certain embodiments, the subject suffers from an HBV-associated disease. In some embodiments, the cell is *in vitro*. In certain embodiments, replication of HBV in the cell is inhibited by at least 80%, 90%, 95%, or 98%, or to below the level of detection of the assay method.

Also provided herein is a method of reducing the level of a Hepatitis B virus (HBV) antigen in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of a dsRNA agent or a pharmaceutical composition as disclosed herein, thereby reducing the level of the HBV antigen in the subject. In  
15 some embodiments, the HBV antigen is HBsAg. In some embodiments, the HBV antigen is HBeAg. In some embodiments, the HBV antigen is measured in serum from a subject. In some embodiments, the subject is HBeAg positive. In some  
20 embodiments, the subject is HBeAg negative. In some embodiments, the HBV antigen level is reduced in serum by at least 1 log<sub>10</sub>, at least 2 log<sub>10</sub>, at least 3 log<sub>10</sub>, or at least 4 log<sub>10</sub>; or to below the level of detection of the assay.

The present disclosure also provides a method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of a dsRNA agent or a pharmaceutical  
25 composition as disclosed herein, thereby reducing the viral load of HBV in the subject. In some embodiments, the HBV viral load is measured in serum from a subject. In  
30 some embodiments, the subject is HBeAg positive. In some embodiments, the subject is HBeAg negative. In some embodiments, the HBV viral load is reduced in serum by at least 1 log<sub>10</sub>, at least 2 log<sub>10</sub>, at least 3 log<sub>10</sub>, or at least 4 log<sub>10</sub>; or to below the level of detection of the assay.

Also provided herein is a method of treating a subject having a Hepatitis B virus (HBV) infection or an HBV-associated disorder, comprising administering to the  
35 subject a therapeutically effective amount of a dsRNA agent a pharmaceutical

composition as disclosed herein, thereby treating the subject. In some embodiments, the subject is HBeAg positive. In some embodiments, the subject is HBeAg negative. In some embodiments, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive. In some embodiments, the HBV-associated disorder is chronic  
5 hepatitis and the subject is HBeAg negative.

In some embodiments of the aforementioned methods, the dsRNA agent is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg, 0.5 mg/kg to 50 mg/kg, or 3 mg/kg to 10 mg/kg. In some embodiments of the methods, the dsRNA agent is administered to the subject at a dose of 3 mg/kg to 10 mg/kg. In some  
10 embodiments of the methods, the dsRNA agent is administered to the subject at a fixed dose of 50 mg to 200 mg.

In some embodiments of the aforementioned methods, the dsRNA agent is administered to the subject subcutaneously.

In some embodiments of the aforementioned methods, the dsRNA agent is  
15 administered to the subject in two or more doses.

In some embodiments of the aforementioned methods, the dsRNA agent is administered to the subject once per month, once every two months, or once every three months. In some embodiments of the methods, the dsRNA agent is administered to the subject no more than once per month.

In some embodiments of the aforementioned methods, the method further  
20 comprises administering to the subject an additional therapeutic agent, *e.g.*, one or more additional therapeutic agents. An additional therapeutic agent can include, but is not limited to, an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion  
25 or release of HbsAg, a capsid inhibitor, and a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing. In some embodiments, the additional therapeutic agent is a reverse transcriptase inhibitor.

In some embodiments, more than one additional therapeutic is administered, and the additional therapeutic agents are a reverse transcriptase inhibitor and an immune  
30 stimulator. A reverse transcriptase inhibitor can include, but is not limited to, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, and AGX-1009. An immune stimulator can include, but is not limited to, pegylated interferon alfa 2a (PEG-IFN- $\alpha$ 2a), Interferon alfa-2b, a recombinant human interleukin-7, and a Toll-like receptor 7 (TLR7) agonist.

35 Also provided herein are compositions for practicing any of the methods disclosed herein. In some embodiments, the disclosure provides a dsRNA agent or a

pharmaceutical composition as disclosed herein for use in the treatment of a Hepatitis B virus (HBV) infection in a subject. In some embodiments, the present disclosure provides a dsRNA agent or a pharmaceutical composition as disclosed herein for use in the treatment of a Hepatitis B virus (HBV)-associated disorder in a subject. In some  
5       embodiments, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive. In some embodiments, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative. In some embodiments, the subject is being or has been administered an additional therapeutic agent, *e.g.*, an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral  
10       entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, or a covalently closed circular (ccc) HBV DNA inhibitor, or a combination of any of the foregoing. In some embodiments, the additional therapeutic agent is a reverse transcriptase inhibitor, *e.g.*, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine,  
15       or AGX-1009. In some embodiments, the additional therapeutic agents being administered are a reverse transcriptase inhibitor (*e.g.*, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, or AGX-1009) and an immune stimulator (*e.g.*, pegylated interferon alfa 2a (PEG-IFN- $\alpha$ 2a), Interferon alfa-2b, a recombinant human interleukin-7, or a Toll-  
20       like receptor 7 (TLR7) agonist).

The present disclosure provides for the use of a dsRNA agent or a pharmaceutical composition as disclosed herein, for practicing any of the aforementioned methods.

The present disclosure also provides for the use of a dsRNA agent as disclosed  
25       herein for the preparation or manufacture of a medicament for practicing any of the aforementioned methods.

The present disclosure also provides kits comprising a dsRNA agent or a pharmaceutical composition as disclosed herein, optionally with instructions for practicing a method described herein.

### 30       BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 schematically depicts the structure of the approximately 3.2 kb double stranded HBV genome. Replication of the HBV genome occurs through an RNA intermediate and produces 4 overlapping viral transcripts (an about 3.5 kb transcript, an about 2.4 kb transcript, an about 2.1 kb transcript, and an about 0.7 kb transcript)

encoding seven viral proteins (pre-S1, pre-S2, S, P, X, pre-C, and C) translated across three reading frames.

Figures 2A-2B show the (A) serum HBsAg concentrations (ng/mL) and (B) serum HBsAg levels relative to pre-dose in the AAV-HBV mouse model. Figure 2A shows serum levels of HBsAg of HBV-AAV mice pre-dose (Days -24, -2, 0), or following a single dose of AD-81890 at 0.3, 1, or 3mg/kg (Days 14, 21, 33, 47, 59, 74). Each point represents a mean of n=6-9 animals and the bars represent SD. Figure 2B shows serum levels of HBsAg of HBV-AAV mice relative to pre-dose (Days -24, -2, 0), or following a single dose of AD-81890 at 0.3, 1, or 3mg/kg (Days 14, 21, 33, 47, 59, 74). Each point represents a mean of n of 6-9 animals and the bars represent SD.

Figure 3 shows the serum HBsAg levels relative to pre-dose in the AAV-HBV mouse model on Days -55, -27, -13, 0, 14, 28, 42, 56, 84, 112, and 140. Dosing regimens included control (PBS) Q2W x 6; AD-66810 (1 mg/kg; Q2W x 6); AD-81890 (1 mg/kg; Q2W x 6); AD-81890 (1 mg/kg; QM x 3); AD-81890 (3 mg/kg; Q2W x 6); AD-81890 (3 mg/kg; QM x 3); and AD-81890 (9 mg/kg; QM x 1). The first dose was administered at Day 0. Each point represents a mean of n of 4-6 animals and the bars represent SD.

Figure 4 shows boxplots showing log<sub>2</sub> Fold Change (treatment/control) for all genes that are significantly downregulated (adjusted p-value < 0.05, log<sub>2</sub> Fold Change < 0) in AD-66810 or AD-81890. Thick horizontal lines represent median log<sub>2</sub> Fold Change, the vertical range of each box shows the interquartile range (IQR), and the whiskers extend to +/-1.58 IQR/sqrt(N), where N is the number of genes in each group. Statistical significance was assessed using Welch's two-sided, two-sample *t*-test.

Figures 5A-5B show ALT levels in PXB-mice over time following administration of AD-66810 (Figure 5A) or AD-81890 (Figure 5B), relative to mice administered PBS. Mice were dosed on Days 0, 21, 28, 35, and 42 with 12, 36, or 100 mg/kg of AD-66810, AD-81890, or PBS (control) by subcutaneous injection (n=4 per group). Blood was collected by retro-orbital bleed twice weekly and serum was prepared using routine methods.

### 30 DETAILED DESCRIPTION

The present disclosure provides dsRNA agent compositions that affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a Hepatitis B virus (HBV) gene. The gene may be within a cell, *e.g.*, a cell within a subject, such as a human. The use of these dsRNA agents enables the targeted degradation of mRNAs of the corresponding gene (HBV gene) in mammals.

The dsRNA agents described herein have been designed to target regions in the HBV genome that are conserved across at least eight known genotypes of HBV. In addition, the dsRNA agents of the present disclosure have been designed to inhibit all steps of the HBV life cycle, *e.g.*, replication, assembly, secretion of virus, and secretion of sub-viral antigens, by inhibiting expression of more than one HBV gene. In particular, since transcription of the HBV genome results in polycistronic, overlapping RNAs, in some embodiments a dsRNA agent targeting a single HBV gene results in significant inhibition of expression of most or all HBV transcripts. For example, because the HBV genome is transcribed into a single mRNA, a dsRNA agent of the present disclosure targeting the S gene will result in inhibition of not only S gene expression but also the expression of the “downstream” polymerase gene. Furthermore, the dsRNA agents of the present disclosure have been designed to inhibit HBV viral replication by targeting HBV structural genes, and the HBV X gene thereby permitting a subject’s immune system to detect and respond to the presence of HBsAg to produce anti-HBV antibodies to clear an HBV infection. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites or the specific modifications in these dsRNA agents confer to the dsRNA agents of the present disclosure improved efficacy, stability, safety, potency, and durability.

Using *in vitro* and *in vivo* assays, the present inventors have demonstrated that dsRNA agents targeting an HBV gene can potently mediate RNAi, resulting in significant inhibition of expression of more than one HBV gene. Thus, methods and compositions including these dsRNA agents are useful for treating a subject having an HBV infection or an HBV-associated disease, such as chronic hepatitis B (CHB).

Accordingly, the present disclosure also provides methods for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of an HBV gene, *e.g.*, an HBV-associated disease, such as chronic Hepatitis B virus infection (CHB), using dsRNA agent compositions that affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an HBV gene.

The dsRNA agents of the present disclosure include an RNA strand (the antisense strand) having a region of complementarity that is about 19-21 nucleotides in length, *e.g.*, about 19 nucleotides in length that is substantially complementary to at least part of an mRNA transcript of an HBV gene of at least one HBV genotype. It is understood that there are multiple HBV genotypes such that a dsRNA agent of the present disclosure may vary in its degree of complementarity to different HBV genotypes.

In some embodiments, the sense and antisense strands form a duplex of 19-21 contiguous nucleotides.

The following detailed description discloses how to make and use compositions containing dsRNA agents to inhibit the expression of an HBV gene as well as  
5 compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition or reduction of the expression of an HBV gene.

#### I. Definitions

In order that the present disclosure may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of  
10 values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this feature.

Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as “comprises” and “comprising,” are to be construed in an open, inclusive sense, that is, as “including, but  
15 not limited to”. “Consisting of” shall mean excluding more than trace elements of other ingredients or substantial method steps disclosed herein. For example, a polynucleotide consists of a sequence of nucleotides when it does not include any additional nucleotides, but does not preclude the incorporation of a ligand, *e.g.*, a targeting ligand, or modifications. The term “consisting essentially of” limits the scope of a claim to the  
20 specified materials or steps, or to those that do not materially affect the basic characteristics of a claimed invention. For example, a pharmaceutical composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.  
25 Similarly, a polynucleotide consists essentially of a nucleotide sequence when the polynucleotide includes additional nucleotides that contribute to at most 20% of the length of the polynucleotide and do not substantially affect activity of the polynucleotide (*e.g.*, alters the activity of the polynucleotide by no more than 50%). Embodiments defined by each of the transitional terms are within the scope of this  
30 invention.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, *e.g.*, a plurality of elements.

The term “including” is used herein to mean, and is used interchangeably with,  
35 the phrase “including but not limited to.”

The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise. For example, “sense strand or antisense strand” is understood as “sense strand or antisense strand or sense strand and antisense strand.”

5           The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as within 2 standard deviations from the mean. When “about” is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

10           The term “at least” prior to a number or series of numbers is understood as each number in the series and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 18 nucleotides of a 21 nucleotide nucleic acid molecule” means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is  
15 understood that “at least” can modify each of the numbers in the series or range.

          As used herein, “no more than” or “less than” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of “no more than 2 nucleotides” has a 2,  
20 1, or 0 nucleotide overhang. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range.

          As used herein, ranges include both the upper and lower limit.

          In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes  
25 precedence.

          Various embodiments of the present disclosure can be combined as determined appropriate by one of skill in the art.

          As used herein, “Hepatitis B virus,” used interchangeably with the term “HBV” refers to the well-known non-cytopathic, liver-tropic DNA virus belonging to the  
30 Hepadnaviridae family.

          The HBV genome is partially double-stranded, circular DNA with overlapping reading frames (*see, e.g.*, Figure 1).

          There are four transcripts (that may be referred to herein as “genes” or “open reading frames”) based on size, encoded by the HBV genome. These contain open  
35 reading frames called C, X, P, and S. The core protein is coded for by gene C (HBcAg). Hepatitis B e antigen (HBeAg) is produced by proteolytic processing of the

pre-core (pre-C) protein. The DNA polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigens (HBsAg). The HBsAg gene is one long open reading frame that contains three in frame “start” (ATG) codons resulting in polypeptides of three different sizes called large, middle, and small S antigens, pre-S1 +  
5 pre-S2 + S, pre-S2 + S, or S. Surface antigens in addition to decorating the envelope of HBV, are also part of subviral particles, which are produced at large excess as compared to virion particles, and play a role in immune tolerance and in sequestering anti-HBsAg antibodies, thereby allowing for infectious particles to escape immune detection. The function of the non-structural protein coded for by gene X is not fully  
10 understood, but it plays a role in transcriptional transactivation and replication and is associated with the development of liver cancer.

HBV is one of the few DNA viruses that utilize reverse transcriptase in the replication process, which involves multiple stages including entry, uncoating, and transport of the virus genome to the nucleus. Initially, replication of the HBV genome  
15 involves the generation of an RNA intermediate that is then reverse transcribed to produce the DNA viral genome.

Upon infection of a cell with HBV, the viral genomic relaxed circular DNA (rcDNA) is transported into the cell nucleus and converted into episomal covalently closed circular DNA (cccDNA), which serves as the transcription template for the viral  
20 mRNAs. After transcription and nuclear export, cytoplasmic viral pregenomic RNA (pgRNA) is assembled with HBV polymerase and capsid proteins to form the nucleocapsid, inside which polymerase-catalyzed reverse transcription yields minus-strand DNA, which is subsequently copied into plus-strand DNA to form the progeny rcDNA genome. The mature nucleocapsids are then either packaged with viral  
25 envelope proteins to egress as virion particles or shuttled to the nucleus to amplify the cccDNA reservoir through the intracellular cccDNA amplification pathway. cccDNA is an essential component of the HBV replication cycle and is responsible for the establishment of infection and viral persistence.

HBV infection results in the production of two different particles: 1) the  
30 infectious HBV virus itself (or Dane particle), which includes a viral capsid assembled from the HBcAg and is covered by an envelope consisting of a lipid membrane with HBV surface antigens, and 2) subviral particles (or SVPs) that contain the small and medium forms of the hepatitis B surface antigen HBsAg, which are non-infectious. For each viral particle produced, over 10,000 SVPs are released into the blood. As such,  
35 SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral

protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).

Eight genotypes of HBV, designated A to H, have been determined, and two additional genotypes I and J have been proposed, each having a distinct geographical  
5 distribution. The virus is non-cytopathic, with virus-specific cellular immunity being the main determinant for the outcome of exposure to HBV- acute infection with resolution of liver diseases with 6 months, or chronic HBV infection that is frequently associated with progressive liver injury.

The term “HBV” includes any of the genotypes of HBV (A to J). The complete  
10 coding sequence of the reference sequence of the HBV genome may be found in for example, GenBank Accession Nos. GI:21326584 (SEQ ID NO:1) and GI:3582357 (SEQ ID NO:3). Antisense sequences are provided in SEQ ID NO:2 and SEQ ID NO:4, respectively. Amino acid sequences for the C, X, P, and S proteins can be found, for example at NCBI Accession numbers YP\_009173857.1 (C protein) (SEQ ID  
15 NO:37); YP\_009173867.1 and BAA32912.1 (X protein) (SEQ ID Nos: 36 and 40); YP\_009173866.1 and BAA32913.1 (P protein) (SEQ ID Nos:32 and 38); and YP\_009173869.1, YP\_009173870.1, YP\_009173871.1, and BAA32914.1 (S protein) (SEQ ID NOs: 33, 34, 35, 39). Protein and DNA sequences from HBV genotype D, strain ayw are provided in SEQ ID NOs: 36-37. Protein and DNA sequences from  
20 HBV genotype C are provided in SEQ ID NOs: 38-39. Additional examples of HBV protein and DNA sequences, or their reverse complements, are provided in SEQ ID Nos: 41-49.

Additional examples of HBV mRNA sequences are readily available using publicly available databases, *e.g.*, GenBank, UniProt, and OMIM. The International  
25 Repository for Hepatitis B Virus Strain Data can be accessed at <http://www.hpa-bioinformatics.org.uk/HepSEQ/main.php>.

The term “HBV,” as used herein, also refers to naturally occurring DNA sequence variations of the HBV genome, *e.g.*, Genotypes A-J and variants thereof.

As used herein, “Hepatitis D virus,” used interchangeably with the term “HDV”  
30 refers to the well-known noncytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family. *See, e.g.*, Ciancio and Rizzetto, *Nat. Rev.* 11:68-71, 2014; Le Gal *et al.*, *Emerg. Infect. Dis.* 12:1447-1450, 2006; and Abbas and Afzal, *World J. Hep.*, 5:666-675, 2013, all of which are incorporated by reference. Unless otherwise indicated, HDV refers to all clades and variants of HDV.

35 HDV produces one protein, namely HDAg. It comes in two forms; a 27kDa large-HDAg (also referred to as LHD, L-HDAg, and large HDV antigen), and a small-

HDAG of 24kDa (also referred to as sHD, S-HDAG, and small HDV antigen). The N-terminals of the two forms are identical; they differ by 19 amino acids in the C-terminal of the large HDAG. Both isoforms are produced from the same reading frame, which contains an UAG stop codon at codon 196 and normally produces only the small-  
5 HDAG. However, editing by cellular enzyme adenosine deaminase-1 changes the stop codon to UCG, allowing the large-HDAG to be produced. Despite having 90% identical sequences, these two proteins play diverging roles during the course of an infection. HDAG-S is produced in the early stages of an infection and enters the nucleus and supports viral replication. HDAG-L, in contrast, is produced during the later stages of  
10 an infection, acts as an inhibitor of viral replication, and is required for assembly of viral particles.

Additional examples of HDV mRNA sequences are readily available using publicly available databases, *e.g.*, GenBank, UniProt, and OMIM.

The term “HDV,” as used herein, also refers to naturally occurring DNA  
15 sequence variations of the HDV genome.

As used herein, the term “nucleot(s)ide analog” or “reverse transcriptase inhibitor” is an inhibitor of DNA replication that is structurally similar to a nucleotide or nucleoside and specifically inhibits replication of the HBV cccDNA and does not significantly inhibit the replication of the host (*e.g.*, human) DNA. Such inhibitors  
20 include Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, besifovir (ANA-380/LB-80380), and tenofvir-exaliades (TLX/CMX157). In certain  
25 embodiments, the nucleot(s)ide analog is Entecavir (ETV). Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (*e.g.*, typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.

As used herein, “target sequence” refers to a contiguous portion of the  
30 nucleotide sequence of an mRNA molecule formed during the transcription of an HBV gene, including mRNA that is a product of RNA processing of a primary transcription product. In some embodiments, the target portion of the sequence will be at least long enough to serve as a substrate for dsRNA agent-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an  
35 HBV gene.

The target sequence may be about 19 to 21 nucleotides in length, *e.g.*, 19, 20, or 21 nucleotides in length.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (*see, e.g.*, Table 1). The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the present disclosure by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the present disclosure.

The terms “dsRNA agent,” “RNAi agent,” “iRNA agent,” “iRNA,” and “RNA interference agent” as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and that mediates the targeted cleavage of an RNA transcript *via* an RNA-induced silencing complex (RISC) pathway. A dsRNA agent directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The dsRNA agent modulates, *e.g.*, inhibits, the expression of an HBV gene (*e.g.*, one or more HBV genes) in a cell, *e.g.*, a cell within a subject, such as a mammalian subject.

An “dsRNA agent” for use in the compositions, uses, and methods disclosed herein is a double stranded RNA and is referred to herein as a “dsRNA agent,” “double stranded RNA agent,” “double stranded RNA (dsRNA) molecule,” “dsRNA,” “iRNA,” “iRNA agent,” “dsRNAi agent,” “RNAi agent,” or “siRNA.” The term “dsRNA” refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, *i.e.*, an HBV gene.

In some embodiments of the present disclosure, a dsRNA triggers the degradation of a target RNA, *e.g.*, an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.

In general, each strand of a dsRNA molecule may contain ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, *e.g.*, a deoxyribonucleotide or a modified nucleotide. In addition, as used in this specification, a “dsRNA agent” may include ribonucleotides with chemical modifications; a dsRNA agent may include substantial modifications at multiple nucleotides. As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions, or removal of, *e.g.*, a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the present disclosure include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA agent-type molecule, are encompassed by “dsRNA agent” for the purposes of this specification and claims.

The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating,” “suppressing,” and other similar terms, and includes any level of inhibition. Preferably inhibiting includes a statistically significant or clinically significant inhibition.

The phrase “inhibiting expression of HBV” or “inhibiting expression of an HBV gene” as used herein, includes inhibition of expression of any HBV gene (*e.g.*, an HBV gene expressed from HBV in an HBV viral infection, an HBV gene expressed from an expression construct in a cell) as well as variants or mutants of an HBV gene that encode an HBV protein. The terms include knockdown of any HBV transcript (*e.g.*, 3.5 kb, 2.4 kb, 2.1 kb, or 0.7 kb transcript) encoding one or more HBV viral protein (such as, *e.g.*, preS1/2-S, preS, S, P, X, preC, and C), as well as variants or mutants of an HBV gene.

“Inhibiting expression of an HBV gene” includes any level of inhibition of an HBV gene or transcript, *e.g.*, at least partial suppression of the expression of an HBV gene, *e.g.* HBV gene S, P, X, or C, or any combination thereof, *e.g.*, S, P, and C. The expression of the HBV gene may be assessed based on the level, or the change in the level, of any variable associated with HBV gene expression, *e.g.*, an HBV mRNA level or an HBV protein level, or HBV cccDNA level. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject, *e.g.*, levels may be monitored in serum. Inhibition may be assessed by a

decrease in an absolute or relative level of one or more of these variables compared with a control level. The control level may be any type of control level that is utilized in the art, *e.g.*, a pre-dose baseline level, or a level determined from a similar subject or population average from an appropriate control subject, cell, or sample that is untreated  
 5 or treated with a control (*e.g.*, buffer only control or inactive agent control).

In some embodiments of the methods of the present disclosure, expression of an HBV gene is inhibited by at least 80%, 85%, 90%, 95%, *e.g.*, in a subject by at least 1 log 10, 2 log 10, 3 log 10, or 4 log 10, or to below the level of detection of the assay. In preferred embodiments, the inhibition of expression of an HBV gene in a subject results  
 10 in a clinically relevant inhibition of the level of gene expression, *e.g.*, sufficiently inhibited to permit an effective immune response against an HBV protein, either when administered alone or in combination with other agents to promote or potentiate an immune response.

In an *in vitro* cell- based assay or expression of a heterologous gene in an *in vivo*  
 15 model, *e.g.*, the mouse AAV-hHBV model provided herein, inhibition of total HBV expression by at least 90% is preferred, *e.g.*, at least 1 log 10, 2 log10, or 3 log10. In treatment of a subject with an HBV infection, a decrease of at least 90% of the HBV gene or protein level, *i.e.*, the difference in the HBV gene or protein level before and after treatment, is preferred. More than one dose may be required to achieve the desired  
 20 level of inhibition.

Inhibition of the expression of an HBV gene may be manifested by a reduction of the amount of RNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an HBV gene is transcribed and which has or have been treated (*e.g.*, by contacting the cell or cells with  
 25 an dsRNA agent of the present disclosure, or by administering an dsRNA agent of the present disclosure to a subject in which the cells are or were present) such that the expression of an HBV gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). In preferred embodiments, the inhibition is assessed by  
 30 the rtPCR method provided in Example 2 of WO2016/077321 (which method is incorporated herein by reference), with *in vitro* assays being performed in an appropriately matched cell line with the duplex at a 10 nM concentration, and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:

$$\frac{(\text{mRNA in control cells}) - (\text{mRNA in treated cells})}{(\text{mRNA in control cells})} \bullet 100\%$$

35

Alternatively, inhibition of the expression of an HBV gene may be assessed in terms of a reduction of a parameter that is functionally linked to HBV gene expression. HBV gene silencing may be determined in any cell expressing an HBV gene, either  
5 constitutively or by genomic engineering, and by any assay known in the art.

Inhibition of the expression of an HBV protein may be manifested by a reduction in the level of an HBV protein that is expressed by a cell or group of cells (*e.g.*, the level of protein expressed in a sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression  
10 levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells or in serum.

A control cell or group of cells that may be used to assess the inhibition of the expression of an HBV gene includes a cell or group of cells that has not yet been contacted with a dsRNA agent of the present disclosure. For example, the control cell  
15 or group of cells may be derived from an individual subject (*e.g.*, a human or animal subject) prior to treatment of the subject with a dsRNA agent. In alternative embodiments, the level may be compared to an appropriate control sample, *e.g.*, a known population control sample.

The level of HBV RNA that is expressed by a cell or group of cells, or the level  
20 of circulating HBV RNA, may be determined using any method known in the art for assessing mRNA expression, preferably using the rtPCR method provided in Example 2 of WO2016/077321. In some embodiments, the level of expression of an HBV gene (*e.g.*, total HBV RNA, an HBV transcript, *e.g.*, HBV 3.5 kb transcript) in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, *e.g.*, RNA of  
25 the HBV gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kits (Qiagen®) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton *et al.*, *Nuc. Acids Res.* 12:7035), northern blotting, *in situ* hybridization, and microarray analysis. Circulating HBV mRNA may be detected using methods the described in WO  
30 2012/177906, which methods are hereby incorporated herein by reference.

In some embodiments, the level of expression of an HBV gene is determined using a nucleic acid probe. The term “probe,” as used herein, refers to any molecule  
35 that is capable of selectively binding to a specific HBV gene. Probes can be synthesized by one of skill in the art, or derived from appropriate biological

preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated RNA can be used in hybridization or amplification assays that include, but are not limited to, northern analyses, polymerase chain reaction (PCR) analyses, and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to an HBV mRNA. In some embodiments, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In some other embodiments, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix® gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of an HBV mRNA.

An alternative method for determining the level of expression of an HBV gene in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, *e.g.*, by RT-PCR (the experimental embodiment set forth in Mullis, 1987, US Patent No. 4,683,202), ligase chain reaction (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189-193), self-sustained sequence replication (Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.* (1988) *Bio/Technology* 6:1197), rolling circle replication (Lizardi *et al.*, US Patent No. 5,854,033), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the present disclosure, the level of expression of an HBV gene is determined by quantitative fluorogenic RT-PCR (*i.e.*, the TaqMan™ System), *e.g.*, using the method provided herein.

The expression levels of an HBV RNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, dot, and the like), or microwells, sample tubes, gels, beads, or fibers (or any solid support comprising bound nucleic acids). *See* US Patent Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195, and 5,445,934, which are incorporated herein by reference for teachings relevant to such methods. The determination of HBV expression level may also comprise using nucleic acid probes in solution.

In preferred embodiments, the level of RNA expression is assessed using real time PCR (qPCR). The use of these methods is described and exemplified in Example 2 of WO2016/077321.

The level of HBV protein expression may be determined using any method  
5 known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitating reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion  
10 (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.

#### dsRNA agents

The duplex region may be of any length that permits specific degradation of a  
15 desired target RNA through a RISC pathway, and may range from about 19-21 base pairs in length, for example, about 19, 20, or 21 base pairs in length. Exemplary dsRNA agents provided herein include duplex lengths of 19-21 base pair.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently  
20 connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a "linker." The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the  
25 shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, a dsRNA agent may comprise one or more nucleotide overhangs.

As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the duplex structure of a double stranded dsRNA agent.  
30 For example, when a 3'-end of one strand of a dsRNA extends beyond the 5'-end of the other strand, or *vice versa*, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise two nucleotides. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense  
35 strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s)

of an overhang can be present on the 5'-end, 3'-end, or both ends of either an antisense or sense strand of a dsRNA. In a preferred embodiment, the nucleotide overhang is on the 3' end of the antisense strand.

“Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the double stranded dsRNA agent, *i.e.*, no nucleotide overhang. A “blunt ended” dsRNA agent is a dsRNA that is double stranded over its entire length, *i.e.*, no nucleotide overhang at either end of the molecule. In some embodiments, the dsRNA agents of the present disclosure include dsRNA agents with nucleotide overhangs at one end (*i.e.*, agents with one overhang and one blunt end) or with nucleotide overhangs at both ends.

The term “antisense strand” or “guide strand” refers to the strand of a dsRNA agent, which includes a region that is substantially complementary to a target sequence, *e.g.*, a HBV mRNA. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, *e.g.*, an HBV nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, *e.g.*, within 5, 4, 3, 2, or 1 nucleotides of the 5'- or 3'-terminus of the dsRNA agent. In some embodiments, a dsRNA agent of the present disclosure includes a nucleotide mismatch in the antisense strand. In some embodiments, a dsRNA agent of the present disclosure includes a nucleotide mismatch in the sense strand. In some embodiments, the nucleotide mismatch is, for example, within 5, 4, 3, 2, or 1 nucleotides from the 3'-terminus of the dsRNA agent. In some embodiments, the nucleotide mismatch is, for example, in the 3'-terminal nucleotide of the dsRNA agent.

The term “sense strand” or “passenger strand” as used herein, refers to the strand of a dsRNA agent that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours followed by

washing (*see, e.g.*, “Molecular Cloning: A Laboratory Manual, Sambrook, *et al.* (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions as can be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of  
5 complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

Complementary sequences within a dsRNA agent, *e.g.*, within a dsRNA agent as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide  
10 comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not  
15 more than 4, 3, or 2 mismatched base pairs upon hybridization for a duplex up to 21 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, *e.g.*, inhibition of gene expression *via* a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches  
20 with regard to the determination of complementarity. For example, a dsRNA agent comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.

25 “Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogstein base pairing.

30 The terms “complementary,” “fully complementary,” and “substantially complementary” herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a dsRNA agent and a target sequence, as will be understood from the context of their use. It is understood that multiple HBV genotypes are known. Therefore, a dsRNA agent  
35 designed to be fully complementary to one HBV genotype may not be fully complementary to all HBV genotypes. A dsRNA agent targeted to a specific site is

effective at target knockdown across multiple genotypes without being fully complementary across all genotypes.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially  
5 complementary to a contiguous portion of the mRNA of interest (*e.g.*, an mRNA encoding an HBV gene). For example, a polynucleotide is complementary to at least a part of an HBV mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding an HBV gene.

Accordingly, in some embodiments, the antisense strand polynucleotides  
10 disclosed herein are fully complementary to the target HBV sequence. In some other embodiments, the antisense strand polynucleotides disclosed herein are substantially complementary to the target HBV sequence and comprise a contiguous nucleotide sequence that is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1,  
15 such as at least 80%, 85%, 90%, or 95% complementary.

In some embodiments, a dsRNA agent of the present disclosure includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is complementary to a target HBV sequence, and wherein the sense strand  
20 polynucleotide comprises a contiguous nucleotide sequence that is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NO:2, such as at least 85%, 90%, or 95% complementary.

In some embodiments, a dsRNA agent includes an antisense strand that is substantially complementary to the target HBV sequence and comprises a contiguous  
25 nucleotide sequence that is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of the sense nucleotide sequences in Table 2, or a fragment of any one of the sense nucleotide sequences in Table 2, such as at least 85%, 90%, or 95% complementary.

As described in detail herein, each or both strands can also include one or more non-ribonucleotides, *e.g.*, a deoxyribonucleotide or a modified nucleotide. In addition,  
30 a dsRNA agent may include ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA agent, may be encompassed by “dsRNA agent” for the purposes of this specification and claims.

In some embodiments, the majority of nucleotides of each strand are  
35 ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, *e.g.*, a deoxyribonucleotide or a modified nucleotide.

In addition, a dsRNA agent may include ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA agent, are encompassed by “dsRNA agent” and “dsRNA agent” for the purposes of this specification and claims.

5           The term “lower” in the context of the level of HBV gene expression or HBV protein production in a subject, or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 80%, 85%, 90%, or 95%, or below the level of detection for the detection method, or more towards or to a normal level (which may or may not be zero). In monitoring of HBV infection,  
10 a log<sub>10</sub> scale is typically used to describe the level of antigenemia (*e.g.*, HBsAg level in serum) or viremia (HBV DNA level in serum). It is understood that 1 log<sub>10</sub> decrease is a 90% decrease (10% remaining), a 2 log<sub>10</sub> decrease is a 99% decrease (1% remaining), *etc.* In certain embodiments, a disease marker is lowered to below the level of detection. In certain embodiments, the methods include a clinically relevant  
15 inhibition of expression of HBV, *e.g.*, as demonstrated by a clinically relevant outcome after treatment of a subject with an agent to reduce the expression of HBV. In some embodiments, at least partial suppression of the expression of an HBV gene, is assessed by a reduction of the amount of HBV mRNA, which can be isolated from or detected in a first cell or group of cells in which an HBV gene is transcribed and which has or have  
20 been treated such that the expression of an HBV gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells).

In certain embodiments, “lower” or “reduce” is understood as lowering or reducing a level towards or to a normal level, *i.e.*, normalizing a level. In certain  
25 embodiments, the expression of the target is normalized to a level accepted as within the range of normal for an individual without such disorder, *e.g.*, the level of a disease marker, such as, ALT or AST, is decreased to a level accepted as within the range of normal for an individual without such disorder. When the disease associated level is elevated from the normal level, the change is calculated from the upper level of normal  
30 (ULN). When the disease associated level is decreased from the normal level, the change is calculated from the lower level of normal (LLN). The lowering is the percent difference in the change between the subject value and the normal value. For example, a normal AST level can be reported as 10 to 40 units per liter. If a subject with an AST level of 200 units per liter, *i.e.*, 5 times the ULN, 160 units per liter above the upper  
35 level of normal prior to treatment has an AST level of 120 units per liter, *i.e.*, 3 times

the ULN, 80 units per liter above the upper level of normal after treatment, the elevated AST would be lowered towards normal by 50% (80/160).

As another example, a normal ALT level is typically considered to be 7 to 55 units per liter (U/L), making the upper level of normal 55 U/L. A subject with an ALT  
5 level of 100 U/L prior to treatment (45 U/L over the upper level of normal) and 75 U/L after treatment (decreased by 25 U/L), the subject's ALT is lowered towards a normal level by 55% (25/45 x 100%). As used herein, if a disease is associated with an elevated value for a symptom, "normal" is considered to be the upper level of normal. If a disease is associated with a decreased value for a symptom, "normal" is considered  
10 to be the lower level of normal.

The phrase "contacting a cell with a dsRNA agent," such as a dsRNA, as used herein, includes contacting a cell by any possible means. Contacting a cell with a dsRNA agent includes contacting a cell *in vitro* with the dsRNA agent or contacting a cell *in vivo* with the dsRNA agent. The contacting may be done directly or indirectly.  
15 Thus, for example, the dsRNA agent may be put into physical contact with the cell by the individual performing the method, or alternatively, the dsRNA agent may be put into a situation that will permit or cause it to subsequently come into contact with the cell.

Contacting a cell *in vitro* may be done, for example, by incubating the cell with  
20 the dsRNA agent. Contacting a cell *in vivo* may be done, for example, by injecting the dsRNA agent into or near the tissue where the cell is located, or by injecting the dsRNA agent into another area, *e.g.*, the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the dsRNA agent may contain or be coupled to a ligand, *e.g.*, GalNAc<sub>3</sub>, that  
25 directs the dsRNA agent to a site of interest, *e.g.*, the liver. Combinations of *in vitro* and *in vivo* methods of contacting are also possible. For example, a cell may also be contacted *in vitro* with a dsRNA agent and subsequently transplanted into a subject.

In some embodiments, contacting a cell with a dsRNA agent includes "introducing" or "delivering the dsRNA agent into the cell" by facilitating or effecting  
30 uptake or absorption into the cell. Absorption or uptake of a dsRNA agent can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. Introducing a dsRNA agent into a cell may be *in vitro* or *in vivo*. For example, for *in vivo* introduction, dsRNA agent can be injected into a tissue site or administered systemically. *In vitro* introduction into a cell includes methods known in the art such as  
35 electroporation and lipofection. Further approaches are described herein below or are known in the art.

As used herein, a “subject” is an animal, such as a mammal, including any mammal that can be infected with HBV, *e.g.*, a primate (such as a human, a non-human primate, *e.g.*, a monkey, or a chimpanzee), or an animal that is considered an acceptable clinical model of HBV infection, HBV-AAV mouse model (*see, e.g., Yang et al. (2014) Cell and Mol Immunol 11:71*) or the HBV 1.3xfs transgenic mouse model (Guidotti *et al. (1995) J. Virol. 69:6158*). In some embodiments, the subject has a hepatitis B virus (HBV) infection. In some embodiments, the subject has both a hepatitis B virus (HBV) infection and a hepatitis D virus (HDV) infection. In some embodiments, the subject is a human, such as a human being having an HBV infection, especially a chronic hepatitis B virus (HBV) infection.

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, alleviation or amelioration of one or more signs or symptoms associated with unwanted HBV gene expression or HBV replication, *e.g.*, the presence of serum or liver HBV cccDNA; the presence of serum HBV DNA; the presence of serum or liver HBV antigen, *e.g.*, HBsAg or HBeAg; elevated ALT; elevated AST (normal range is typically considered about 10 to 34 U/L); the absence or low level of anti-HBV antibodies, a liver injury; cirrhosis; delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma; serum sickness-like syndrome; anorexia; nausea; vomiting, low-grade fever; myalgia; fatigability; disordered gustatory acuity and smell sensations (aversion to food and cigarettes); right upper quadrant and epigastric pain (intermittent, mild to moderate); hepatic encephalopathy; somnolence; disturbances in sleep pattern; mental confusion; coma; ascites; gastrointestinal bleeding; coagulopathy; jaundice; hepatomegaly (mildly enlarged, soft liver); splenomegaly; palmar erythema; spider nevi; muscle wasting; spider angiomas; vasculitis; variceal bleeding; peripheral edema; gynecomastia; testicular atrophy; abdominal collateral veins (caput medusa); ALT levels higher than AST levels; elevated gamma-glutamyl transpeptidase (GGT) (normal range is typically considered about 8 to 65 U/L) and alkaline phosphatase (ALP) levels (normal range is typically considered about 44 to 147 IU/L (international units per liter), not more than 3 times the ULN); slightly low albumin levels; elevated serum iron levels; leukopenia (*i.e.*, granulocytopenia); lymphocytosis; increased erythrocyte sedimentation rate (ESR); shortened red blood cell survival; hemolysis; thrombocytopenia; a prolongation of the international normalized ratio (INR); presence of serum or liver HBsAg, HBeAg, or Hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM); presence of hepatitis B surface antibody (anti-HBs), hepatitis B e antibody (anti-HBe), or HBV DNA; increased bilirubin levels;

hyperglobulinemia; the presence of tissue-nonspecific antibodies, such as anti-smooth muscle antibodies (ASMAs) or antinuclear antibodies (ANAs) (10-20%); the presence of tissue-specific antibodies, such as antibodies against the thyroid gland (10-20%); elevated levels of rheumatoid factor (RF); low platelet and white blood cell counts; lobular, with degenerative and regenerative hepatocellular changes, and accompanying inflammation; and predominantly centrilobular necrosis, whether detectable or undetectable. The likelihood of developing liver fibrosis, is reduced, for example, when an individual having one or more risk factors for liver fibrosis, *e.g.*, chronic hepatitis B infection, either fails to develop liver fibrosis or develops liver fibrosis with less severity relative to a population having the same risk factors and not receiving treatment as described herein. The failure to develop a disease, disorder, or condition, or the reduction in the development of a sign or symptom associated with such a disease, disorder, or condition (*e.g.*, by a clinically relevant amount), or the exhibition of delayed signs or symptoms delayed (*e.g.*, by days, weeks, months, or years) is considered effective prevention. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment. Prevention may require the administration of more than one dose.

In preferred embodiments, treatment of HBV infection results in a “functional cure” of hepatitis B. As used herein, functional cure is understood as clearance of circulating HBsAg and is preferably accompanied by conversion to a status in which HBsAg antibodies become detectable using a clinically relevant assay. For example, detectable antibodies can include a signal higher than 10 mIU/ml as measured by Chemiluminescent Microparticle Immunoassay (CMIA) or any other immunoassay called anti-HBs seroconversion. Functional cure does not require clearance of all replicative forms of HBV (*e.g.*, cccDNA from the liver). Anti-HBs seroconversion occurs spontaneously in about 0.2-1% of chronically infected patients per year. However, even after anti-HBs seroconversion, low level persistence of HBV is observed for decades indicating that a functional rather than a complete cure occurs. Without being bound to mechanism, it is proposed that the immune system is able to keep HBV in check. A functional cure permits discontinuation of any treatment for the HBV infection. However, it is understood that a “functional cure” for HBV infection may not be sufficient to prevent or treat diseases or conditions that result from HBV infection, *e.g.*, liver fibrosis, HCC, cirrhosis.

As used herein, the term “Hepatitis B virus-associated disease” or “HBV-associated disease,” is a disease or disorder that is caused by, or associated with HBV infection or replication. The term “HBV-associated disease” includes a disease,

disorder, or condition that would benefit from reduction in HBV gene expression or replication. Non-limiting examples of HBV-associated diseases include, for example, hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; and hepatocellular carcinoma.

5 In some embodiments, an HBV-associated disease is hepatitis D virus infection. Hepatitis D virus or hepatitis delta virus (HDV) is a human pathogen. However, the virus is defective and depends on obligatory helper functions provided by hepatitis B virus (HBV) for transmission; indeed, HDV requires an associated or pre-existing HBV infection to become infectious and thrive, in particular, the viral envelope containing  
10 the surface antigen of hepatitis B. HDV can lead to severe acute and chronic forms of liver disease in association with HBV. Hepatitis D infection or delta hepatitis is highly endemic to several African countries, the Amazonian region, and the Middle East, while its prevalence is low in industrialized countries, except in the Mediterranean.

Transmission of HDV can occur either *via* simultaneous infection with HBV  
15 (coinfection) or superimposed on chronic hepatitis B or hepatitis B carrier state (superinfection). Both superinfection and coinfection with HDV results in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in  
20 chronic infections. In combination with hepatitis B virus, hepatitis D has the highest fatality rate of all the hepatitis infections, at 20%.

In some embodiments, an HBV-associated disease is acute hepatitis B. Acute hepatitis B includes inflammation of the liver that lasts less than six months. Typical symptoms of acute hepatitis B are fatigue, anorexia, nausea, and vomiting. Very high  
25 aminotransferase values ( $>1000$  U/L) and hyperbilirubinemia are often observed. Severe cases of acute hepatitis B may progress rapidly to acute liver failure, marked by poor hepatic synthetic function. This is often defined as a prothrombin time (PT) of 16 seconds or an international normalized ratio (INR) of 1.5 in the absence of previous liver disease. Acute hepatitis B may evolve into chronic hepatitis B.

30 In some embodiments, an HBV-associated disease is chronic hepatitis. Chronic hepatitis B (CHB) includes inflammation of the liver that lasts more than six months. Subjects having CHB are HBsAg positive and have either high viremia ( $\geq 10^4$  HBV-DNA copies / ml blood) or low viremia ( $< 10^3$  HBV-DNA copies / ml blood). In some  
35 embodiments, subjects have been infected with HBV for at least five years. In some embodiments, subjects have been infected with HBV for at least ten years. In some embodiments, subjects became infected with HBV at birth. Subjects having chronic

hepatitis B disease can be immune tolerant or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic. Patients with chronic active hepatitis, especially during the replicative state, may have symptoms similar to those of acute hepatitis. Subjects having chronic hepatitis B disease may have an active chronic infection accompanied by necroinflammatory liver disease, have increased hepatocyte turn-over in the absence of detectable necroinflammation, or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic. The persistence of HBV infection in CHB subjects is the result of cccHBV DNA. In some embodiments, a subject having CHB is HBeAg positive. In another embodiment, a subject having CHB is HBeAg negative. Subjects having CHB have a level of serum HBV DNA of less than  $10^5$  and a persistent elevation in transaminases, for examples ALT, AST, and gamma-glutamyl transferase. A subject having CHB may have a liver biopsy score of less than 4 (*e.g.*, a necroinflammatory score).

15 In some embodiments, an HBV-associated disease is acute fulminant hepatitis B. A subject having acute fulminant hepatitis B has symptoms of acute hepatitis and the additional symptoms of confusion or coma (due to the liver's failure to detoxify chemicals) and bruising or bleeding (due to a lack of blood clotting factors).

Subjects having an HBV infection, *e.g.*, CHB, may develop liver fibrosis. Accordingly, in some embodiments, an HBV-associated disease is liver fibrosis. Liver fibrosis, or cirrhosis, is defined histologically as a diffuse hepatic process characterized by fibrosis (excess fibrous connective tissue) and the conversion of normal liver architecture into structurally abnormal nodules.

Subjects having an HBV infection, *e.g.*, CHB, may develop end-stage liver disease. Accordingly, in some embodiments, an HBV-associated disease is end-stage liver disease. For example, liver fibrosis may progress to a point where the body may no longer be able to compensate for, *e.g.*, reduced liver function, as a result of liver fibrosis (*i.e.*, decompensated liver), and result in, *e.g.*, mental and neurological symptoms and liver failure.

30 Subjects having an HBV infection, *e.g.*, CHB, may develop hepatocellular carcinoma (HCC), also referred to as malignant hepatoma. Accordingly, in some embodiments, an HBV-associated disease is HCC. HCC commonly develops in subjects having CHB and may be fibrolamellar, pseudoglandular (adenoid), pleomorphic (giant cell), or clear cell.

35 An "HDV-associated disorder" or a Hepatitis D-virus-associated disorder" is a disease or disorder associated with expression of an HDV. Exemplary HDV-associated

disorders include hepatitis B virus infection, acute hepatitis B, acute hepatitis D; acute fulminant hepatitis D; chronic hepatitis D; liver fibrosis; end-stage liver disease; and hepatocellular carcinoma.

“Therapeutically effective amount,” as used herein, is intended to include the amount of an dsRNA agent that, when administered to a patient for treating a subject having an HBV infection or HBV-associated disease, is sufficient to effect treatment of the disease (*e.g.*, by diminishing or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the dsRNA agent, how the agent is administered, the disease and its severity, and the history, age, weight, family history, genetic makeup, stage of pathological processes mediated by HBV gene expression, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated. A therapeutically effective amount may require the administration of more than one dose.

A “therapeutically-effective amount” also includes an amount of a dsRNA agent that produces some desired effect at a reasonable benefit/risk ratio applicable to any treatment. dsRNA agents employed in the methods of the present disclosure may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum, and serosal fluids, plasma, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (*e.g.*, whole liver or certain segments of liver or certain types of cells in the liver, such as, *e.g.*, hepatocytes). In preferred embodiments, a “sample derived from a subject” refers to blood, or plasma or serum obtained from blood drawn from the subject. In further embodiments, a “sample derived from a subject” refers to liver tissue (or subcomponents thereof) or blood tissue (or subcomponents thereof, *e.g.*, serum) derived from the subject.

## II. dsRNA Agents

The present disclosure provides dsRNA agents that inhibit the expression of one or more HBV genes. In some embodiments, the dsRNA agent includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of an HBV gene in a cell, such as a cell within a subject, *e.g.*, a mammal, such as a human having an HBV-

associated disease, *e.g.*, chronic hepatitis B. The dsRNA agents include an antisense strand having a region of complementarity that is complementary to at least a part of an mRNA formed in the expression of an HBV gene. The region of complementarity is about 19-21 nucleotides in length. Upon contact with a cell expressing the HBV gene, the dsRNA agent inhibits the expression of the HBV gene by at least 80% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flowcytometric techniques. In preferred embodiments, percent inhibition is determined using the real time PCR method provided in Example 2 using a cell line provided therein with the dsRNA agent used at a 10 nM concentration in the transfection.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. However, due to sequence variations among HBV genotypes, the dsRNA may be fully complementary to some, but not all, HBV genotypes. The target sequence can be derived from the sequence of an mRNA formed during the expression of an HBV gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is 19-21 base pairs in length, *e.g.*, 19, 20, or 21 base pairs in length.

Similarly, the region of complementarity to the target sequence is 19-23 nucleotides in length, *e.g.*, 19-23, 19-22, 19-21, 19-20, 20-23, 20-22, 20-21, 21-22, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, the region of complementarity is 21 nucleotides in length. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a "part" of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (*i.e.*, cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, *e.g.*, a duplex region of about 19-21 base pairs, *e.g.*, 19-

21, 19-20, 20-21, 19, 20, or 21 base pairs. In some embodiments, the duplex region is 19 base pairs.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs, *e.g.*, 1 or 2 nucleotides. A nucleotide overhang can comprise or  
5 consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5'-end, 3'-end, or both ends of one or both of an antisense or sense strand of a dsRNA. In some  
10 embodiments, the dsRNA includes a 2-nucleotide overhang on the 3' end of the antisense strand.

A dsRNA can be synthesized by standard methods known in the art as further discussed below, *e.g.*, by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems<sup>TM</sup>, Inc. Methods for synthesis of dsRNAs for use in pharmaceutical compositions are also  
15 known in the art.

dsRNA agent compounds of the present disclosure may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the dsRNA agent compound can be prepared using solution-phase or solid-  
20 phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Single-stranded oligonucleotides of the present disclosure can be prepared using solution-phase or solid-phase organic synthesis or both.

In some embodiments, a dsRNA agent of the present disclosure includes at least  
25 two nucleotide sequences, a sense strand sequence and an antisense strand sequence. The sense strand may comprise a nucleotide sequence selected from the group consisting of any one of the sense strand nucleotide sequences of any one of the duplexes in Table 2. The antisense strand may comprise a nucleotide sequence selected from the group consisting of any one of the antisense strand nucleotide sequences of  
30 any one of the duplexes in Table 2. In some embodiments, the dsRNA agent is not AD-66810.

In some embodiments, a dsRNA agent of the disclosure comprises, consists essentially of, or consists of a sense strand and an antisense strand, as set forth in Table  
2.

### III. Modified dsRNA Agents

In certain embodiments, the RNA of the dsRNA agent of the present disclosure is un-modified, and does not comprise, *e.g.*, chemical modifications or conjugations known in the art and described herein. In other embodiments, the RNA of a dsRNA agent of the present disclosure is chemically modified to enhance stability or other beneficial characteristics. In some embodiments of the present disclosure, substantially all of the nucleotides of a dsRNA agent of the present disclosure are modified. In some embodiments of the present disclosure, all of the nucleotides of a dsRNA agent or substantially all of the nucleotides of a dsRNA agent are modified, *i.e.*, not more than 5, 4, 3, 2, or 1 unmodified nucleotides are present in a strand of the dsRNA agent.

The nucleic acids featured in the present disclosure can be synthesized or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S.L. *et al.* (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which methods are hereby incorporated herein by reference. Modifications include, for example, end modifications, *e.g.*, 5'-end modifications (phosphorylation, conjugation, inverted linkages) or 3'-end modifications (conjugation, DNA nucleotides, inverted linkages, *etc.*); base modifications, *e.g.*, replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (*e.g.*, at the 2'-position or 4'-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of dsRNA agent compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified dsRNA agent will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5'-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of

nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts, and free acid forms are also included.

Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat RE39464, each of which are hereby incorporated herein by reference for teachings relevant to such methods of preparation.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH<sub>2</sub> component parts.

Representative U.S. Patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is hereby incorporated herein by reference for teachings relevant to such methods.

Suitable RNA mimetics are contemplated for use in dsRNA agents provided herein, in which both the sugar and the internucleoside linkage, *i.e.*, the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound in which an RNA mimetic that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing

backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is hereby incorporated herein by reference for teachings relevant to such methods. Additional PNA compounds suitable for use in the dsRNA agents of the present disclosure are described in, for example, in Nielsen *et al.*, *Science*, 1991, 254, 1497-1500.

Some embodiments featured in the present disclosure include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular --CH<sub>2</sub>--NH--CH<sub>2</sub>--, --CH<sub>2</sub>--N(CH<sub>3</sub>)--O--CH<sub>2</sub>--[known as a methylene (methylimino) or MMI backbone], --CH<sub>2</sub>--O--N(CH<sub>3</sub>)--CH<sub>2</sub>--, --CH<sub>2</sub>--N(CH<sub>3</sub>)--N(CH<sub>3</sub>)--CH<sub>2</sub>-- and --N(CH<sub>3</sub>)--CH<sub>2</sub>--CH<sub>2</sub>--[wherein the native phosphodiester backbone is represented as --O--P--O--CH<sub>2</sub>--] of the above-referenced U.S. Patent No. 5,489,677, and the amide backbones of the above-referenced U.S. Patent No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Patent No. 5,034,506.

Modified RNAs can also contain one or more substituted sugar moieties. The dsRNA agents, featured herein can include one of the following at the 2'-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Exemplary suitable modifications include O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a dsRNA agent, or a group for improving the pharmacodynamic properties of a dsRNA agent, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-O--CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, *Helv. Chim. Acta*, 1995, 78:486-504), *i.e.*, an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminoxyethoxy, *i.e.*, a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples herein below, and 2'-

dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), *i.e.*, 2'-O--CH<sub>2</sub>--O--CH<sub>2</sub>--N(CH<sub>2</sub>)<sub>2</sub>. Further exemplary modifications include : 5'-Me-2'-F nucleotides, 5'-Me-2'-OMe nucleotides, 5'-Me-2'-deoxynucleotides, (both R and S isomers in these three families); 2'-alkoxyalkyl; and  
5 2'-NMA (N-methylacetamide).

Other modifications include 2'-methoxy (2'-OCH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of a dsRNA agent, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal  
10 nucleotide. dsRNA agents can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300;  
15 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920; certain of which are commonly owned with the instant application. The contents of each of the foregoing patent publications are hereby incorporated herein by reference for teachings related to such methods.

A dsRNA agent can also include nucleobase (often referred to in the art simply  
20 as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and  
25 other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other  
30 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine, and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Patent No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise  
35 Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L., ed. John Wiley & Sons, 1990, these disclosed by Englisch *et al.*, Angewandte Chemie,

International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the present disclosure. These  
5 include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base  
10 substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative U.S. Patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066;  
15 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, each of which is hereby incorporated herein by reference for teachings relevant to such methods.

20 In some embodiments, the RNA of a dsRNA agent can also be modified to include one or more bicyclic sugar moieties. A "bicyclic sugar" is a furanosyl ring modified by the bridging of two atoms. A "bicyclic nucleoside" ("BNA") is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the  
25 bridge connects the 4'-carbon and the 2'-carbon of the sugar ring. Thus, in some embodiments, an agent of the present disclosure may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety  
30 comprising a 4'-CH<sub>2</sub>-O-2' bridge. This structure effectively "locks" the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to dsRNA agents has been shown to increase dsRNA agent stability in serum, and to reduce off-target effects (Elmen, J. *et al.*, (2005) *Nucleic Acids Research* 33(1):439-447; Mook, OR. *et al.*, (2007) *Mol Canc Ther* 6(3):833-843; Grunweller, A. *et al.*, (2003) *Nucleic Acids  
35 Research* 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the present disclosure include without limitation nucleosides

comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the present disclosure include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to, 4'-(CH<sub>2</sub>)—O-2' (LNA); 4'-(CH<sub>2</sub>)—S-2'; 4'-(CH<sub>2</sub>)<sub>2</sub>—O-2' (ENA); 4'-CH(CH<sub>3</sub>)—O-2' (also referred to as “constrained ethyl” or “cEt”) and 4'-CH(CH<sub>2</sub>OCH<sub>3</sub>)—O-2' (and analogs thereof; *see, e.g.*, U.S. Patent No. 7,399,845); 4'-C(CH<sub>3</sub>)(CH<sub>3</sub>)—O-2' (and analogs thereof; *see, e.g.*, U.S. Patent No. 8,278,283); 4'-CH<sub>2</sub>—N(OCH<sub>3</sub>)-2' (and analogs thereof; *see, e.g.*, U.S. Patent No. 8,278,425); 4'-CH<sub>2</sub>—O—N(CH<sub>3</sub>)-2' (*see, e.g.*, U.S. Patent Publication No. 2004/0171570); 4'-CH<sub>2</sub>—N(R)—O-2', wherein R is H, C1-C12 alkyl, or a protecting group (*see, e.g.*, U.S. Patent No. 7,427,672); 4'-CH<sub>2</sub>—C(H)(CH<sub>3</sub>)-2' (*see, e.g.*, Chattopadhyaya *et al.*, *J. Org. Chem.*, 2009, 74, 118-134); and 4'-CH<sub>2</sub>—C(=CH<sub>2</sub>)-2' (and analogs thereof; *see, e.g.*, U.S. Patent No. 8,278,426). The contents of each of the foregoing relevant to modified nucleic acids are hereby incorporated herein by reference.

Additional representative U.S. Patents and U.S. Patent Publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, which are hereby incorporated herein by reference for teachings relevant to such methods.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example  $\alpha$ -L-ribofuranose and  $\beta$ -D-ribofuranose (*see* WO99/14226).

The RNA of a dsRNA agent can also be modified to include one or more constrained ethyl nucleotides. As used herein, a “constrained ethyl nucleotide” or “cEt” is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH<sub>3</sub>)-O-2' bridge. In some embodiments, a constrained ethyl nucleotide is in the S conformation referred to herein as “S-cEt.”

A dsRNA agent of the present disclosure may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2' and C4' carbons of ribose or the C3 and C5' carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.


Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, U.S. Patent Publication No. 2013/0190383; and PCT publication WO2013/036868, which are hereby incorporated herein by reference for teachings relevant to such methods.

5           In some embodiments, a dsRNA agent of the present disclosure comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked “sugar” residue. In one example, UNA also encompasses monomer with bonds between C1'-C4' have been removed (*i.e.*, the covalent carbon-  
10 oxygen-carbon bond between the C1' and C4' carbons). In another example, the C2'-C3' bond (*i.e.*, the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed (*see Nuc. Acids Symp. Series*, 52, 133-134 (2008) and Fluiter *et al.*, *Mol. Biosyst.*, 2009, 10, 1039, which are hereby incorporated by reference for teachings relevant to unlocked nucleic acid nucleotides).

15           Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Patent No. 8,314,227; and U.S. Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, which are hereby incorporated herein by reference for teachings relevant to such methods.

Potentially stabilizing modifications to the ends of RNA molecules can include  
20 N- (acetylaminoacetyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3'- phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in PCT Publication No. WO2011/005861.

25           In certain embodiments, the dsRNA agent is modified to include one or more adenosine-glycol nucleic acid (“GNA”). The term “GNA” refers to glycol nucleic acid which is a polymer similar to DNA or RNA but differing in the composition of its “backbone” in that is composed of repeating glycerol units linked by phosphodiester bonds:



(R)-GNA

. A description of adenosine-GNA can be found, for example, in Zhang, et al. (JACS 127(12):4174–75 (2005)).

Other modifications of the nucleotides of an dsRNA agent as disclosed herein include a 5' phosphate or 5' phosphate mimic, *e.g.*, a 5'-terminal phosphate or phosphate  
 5 mimic on the antisense strand of an dsRNA agent. Suitable phosphate mimics are disclosed in, for example U.S. Patent Publication No. 2012/0157511, which are hereby incorporated herein by reference for teachings relevant to such modifications.

Additional modified dsRNA agents targeting HBV are provided, for example, in  
 WO2016/077321, which is incorporated herein by reference for teachings relevant to  
 10 modifications.

In some embodiments, a dsRNA agent comprises, consists essentially of, or consists of a modified sense strand and a modified antisense strand, as set forth in Table 2.

IV. dsRNA Agents Conjugated to Ligands

15 The dsRNA agents of the present disclosure may be conjugated to a ligand. A ligand may alter the distribution, targeting or lifetime of a dsRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, *e.g.*, molecule, cell or cell type, compartment, *e.g.*, a cellular or organ compartment, tissue, organ or region of the body, as, *e.g.*, compared to a species absent  
 20 such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligand-conjugated oligonucleotides of the present disclosure may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with  
5 commercially available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present disclosure, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard  
10 nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.


When using nucleotide-conjugate precursors that already bear a linking moiety,  
15 the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present disclosure are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard  
20 phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

Representative U.S. patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,591,584;  
25 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463;  
30 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, which are hereby incorporated herein by reference for teachings relevant to such methods of preparation.


### A. Carbohydrate Conjugates

In preferred embodiments of the compositions and methods disclosed herein, a dsRNA agent oligonucleotide further comprises a carbohydrate. Carbohydrate-conjugated dsRNA agent are advantageous for the *in vivo* delivery of nucleic acids, as well as compositions suitable for *in vivo* therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound that is either a carbohydrate *per se* made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched, or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri-, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose, and polysaccharide gums. Specific monosaccharides include C5 and above (*e.g.*, C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (*e.g.*, C5, C6, C7, or C8).


In some embodiments, a carbohydrate conjugate for use in the compositions and methods of the present disclosure is a monosaccharide. In some embodiments, a carbohydrate conjugate for use in the compositions and methods of the present disclosure is selected from the group consisting of:




Formula I,




Formula II,




Formula III,




Formula IV,




Formula V,




Formula VI,




Formula VII,




Formula VIII,




Formula IX,




Formula X,




Formula XI,




Formula XII,




Formula XIII,




Formula XIV,




Formula XV,




Formula XVI,




Formula XVII,




Formula XVIII,



Formula XIX,




Formula XX, and



Formula XXI.


In some embodiments, the monosaccharide is an N-acetylgalactosamine (GalNAc). In some embodiments, the carbohydrate comprises multiple N-acetylgalactosamine units, such as



5

Formula I.

Another representative carbohydrate conjugate that may be used in the embodiments described herein includes, but is not limited to,



Formula XXII,

10


wherein when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments of the present disclosure, the GalNAc or GalNAc derivative is attached to a dsRNA agent of the present disclosure *via* a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to a dsRNA agent of the present disclosure *via* a bivalent linker. In some embodiments of the present disclosure, the GalNAc or GalNAc derivative is attached to a dsRNA agent of the present disclosure *via* a trivalent linker. In some embodiments, the carbohydrate ligand comprises three N-acetylgalactosamine units attached *via* a trivalent linker (“GalNAc<sub>3</sub>”).


In some embodiments, the double stranded dsRNA agent comprises one GalNAc or GalNAc derivative attached to the dsRNA agent. In some embodiments, the double stranded dsRNA agent comprises a plurality of (*e.g.*, 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded dsRNA agent through a plurality of monovalent linkers.

Additional carbohydrate conjugates suitable for use in the present disclosure include those described in PCT Publication Nos. WO2014/179620 and WO2014/179627, which are incorporated herein by reference for teachings relevant to such conjugates.


Non-limiting examples of dsRNA agent carbohydrate conjugates with linkers that may be used in the compositions and methods of disclosed herein include, but are not limited to,




Formula XXIII,




Formula XXIV,




Formula XXV,



Formula XXVI,




Formula XXVII,




Formula XXVIII,

5



Formula XXIX, and




Formula XXX,


5 wherein when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments of the compositions and methods disclosed herein, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.


In some embodiments, a dsRNA agent as disclosed herein is conjugated to a  
10 bivalent or trivalent branched linker selected from the group of structures shown in any of formulae (XXXI) – (XXXIV):




Formula XXXI,



Formula XXXII,



Formula XXXIII, or



Formula XXXIV;

5


wherein:

q<sup>2A</sup>, q<sup>2B</sup>, q<sup>3A</sup>, q<sup>3B</sup>, q<sup>4A</sup>, q<sup>4B</sup>, q<sup>5A</sup>, q<sup>5B</sup> and q<sup>5C</sup> represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

10 P<sup>2A</sup>, P<sup>2B</sup>, P<sup>3A</sup>, P<sup>3B</sup>, P<sup>4A</sup>, P<sup>4B</sup>, P<sup>5A</sup>, P<sup>5B</sup>, P<sup>5C</sup>, T<sup>2A</sup>, T<sup>2B</sup>, T<sup>3A</sup>, T<sup>3B</sup>, T<sup>4A</sup>, T<sup>4B</sup>, T<sup>4A</sup>, T<sup>5B</sup>, T<sup>5C</sup> are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH<sub>2</sub>, CH<sub>2</sub>NH or CH<sub>2</sub>O;


15 Q<sup>2A</sup>, Q<sup>2B</sup>, Q<sup>3A</sup>, Q<sup>3B</sup>, Q<sup>4A</sup>, Q<sup>4B</sup>, Q<sup>5A</sup>, Q<sup>5B</sup>, Q<sup>5C</sup> are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO<sub>2</sub>, N(R<sup>N</sup>), C(R')=C(R''), C≡C or C(O);

R<sup>2A</sup>, R<sup>2B</sup>, R<sup>3A</sup>, R<sup>3B</sup>, R<sup>4A</sup>, R<sup>4B</sup>, R<sup>5A</sup>, R<sup>5B</sup>, R<sup>5C</sup> are each independently for each occurrence absent, NH, O, S, CH<sub>2</sub>, C(O)O, C(O)NH, NHCH(R<sup>a</sup>)C(O),



L<sup>2A</sup>, L<sup>2B</sup>, L<sup>3A</sup>, L<sup>3B</sup>, L<sup>4A</sup>, L<sup>4B</sup>, L<sup>5A</sup>, L<sup>5B</sup> and L<sup>5C</sup> represent the ligand; *i.e.*, each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R<sup>a</sup> is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with dsRNA agents for inhibiting the expression of a target gene, such as those of formula (XXXIV):

10



Formula XXXIV,

wherein L<sup>5A</sup>, L<sup>5B</sup> and L<sup>5C</sup> represent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas I, VI, X, IX, and XII.

B. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to a dsRNA agent oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term “linker” or “linking group” means an organic moiety that connects two parts of a compound, *e.g.*, covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR<sub>8</sub>, C(O), C(O)NH, SO, SO<sub>2</sub>, SO<sub>2</sub>NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or

unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl,  
 heteroarylalkenyl, heteroarylalkynyl, heterocyclalkyl, heterocyclalkenyl,  
 heterocyclalkynyl, aryl, heteroaryl, heterocycl, cycloalkyl, cycloalkenyl,  
 alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl,  
 5 alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl,  
 alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl,  
 alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl,  
 alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl,  
 alkylheterocyclalkyl, alkylheterocyclalkenyl, alkylheterocyclalkynyl,  
 10 alkenylheterocyclalkyl, alkenylheterocyclalkenyl, alkenylheterocyclalkynyl,  
 alkynylheterocyclalkyl, alkynylheterocyclalkenyl, alkynylheterocyclalkynyl,  
 alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl,  
 alkynylheteroaryl, which one or more methylenes can be interrupted or terminated by  
 O, S, S(O), SO<sub>2</sub>, N(R<sub>8</sub>), C(O), substituted or unsubstituted aryl, substituted or  
 15 unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R<sub>8</sub> is  
 hydrogen, acyl, aliphatic or substituted aliphatic. In some embodiments, the linker is  
 about 1-24, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18, 7-17, 8-17, 6-16, 7-16, or 8-  
 16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but  
 20 which upon entry into a target cell is cleaved to release the two parts the linker is  
 holding together. In some embodiments, the cleavable linking group is cleaved at least  
 about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90  
 times, or more, or at least about 100 times faster in a target cell or under a first  
 reference condition (which can, *e.g.*, be selected to mimic or represent intracellular  
 25 conditions) than in the blood of a subject, or under a second reference condition (which  
 can, *e.g.*, be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, *e.g.*, pH, redox  
 potential, or the presence of degradative molecules. Generally, cleavage agents are  
 more prevalent or found at higher levels or activities inside cells than in serum or blood.  
 30 Examples of such degradative agents include: redox agents, which are selected for  
 particular substrates or which have no substrate specificity, including, *e.g.*, oxidative or  
 reductive enzymes or reductive agents such as mercaptans, present in cells, that can  
 degrade a redox cleavable linking group by reduction; esterases; endosomes or agents  
 that can create an acidic environment, *e.g.*, those that result in a pH of five or lower;  
 35 and enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as  
 a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linking group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a  
5 cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic  
10 lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in  
15 peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other  
20 non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, *e.g.*, blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals.  
25 It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood or serum (or under *in vitro* conditions  
30 selected to mimic extracellular conditions).

i. Redox cleavable linking groups

In some embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate  
35 cleavable linking group is a suitable “reductively cleavable linking group,” or for

example is suitable for use with a particular dsRNA agent moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents known in the art, which mimic the rate of cleavage that would be observed in a cell, *e.g.*, a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In some embodiments, candidate compounds are cleaved by at most about 10% in the blood. In some embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood (or under *in vitro* conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

15                   ii.       Phosphate-based cleavable linking groups

In some embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -O-P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, -O-P(S)(Rk)-S-. In some embodiments, the phosphate-based linking group is -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, or -O-P(S)(H)-S-. In some embodiments, the phosphate-based linking group is -O-P(O)(OH)-O-. These candidates can be evaluated using methods analogous to those described above.

30                   iii.       Acid cleavable linking groups

In some embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In some embodiments, acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (*e.g.*, about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific

low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula  $-C=NN-$ ,  $C(O)O$ , or  $-OC(O)$ . In some embodiments, the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

iv. Ester-based linking groups

In some embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene, and alkynylene groups. Ester cleavable linking groups have the general formula  $-C(O)O-$ , or  $-OC(O)-$ . These candidates can be evaluated using methods analogous to those described above.

v. Peptide-based cleaving groups

In some embodiments, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (*e.g.*, dipeptides, tripeptides, *etc.*) and polypeptides. Peptide-based cleavable groups do not include the amide group ( $-C(O)NH-$ ). The amide group can be formed between any alkylene, alkenylene, or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide-based cleavage group is generally limited to the peptide bond (*i.e.*, the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula –  $NHCHRAC(O)NHCHRBC(O)-$ , where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

#### V. Delivery of a dsRNA Agent

The delivery of a dsRNA agent of the present disclosure to a cell, *e.g.*, a cell within a subject, such as a human subject, can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with a dsRNA agent of the present disclosure either *in vitro* or *in vivo*. *In vivo* delivery may also be performed directly by administering a composition comprising a dsRNA agent, to a subject. Alternatively, *in vivo* delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the dsRNA agent. These alternatives are discussed further below.

10 In general, any method of delivering a nucleic acid molecule (*in vitro* or *in vivo*) can be adapted for use with a dsRNA agent of the present disclosure (*see, e.g.*, Akhtar S. and Julian RL. (1992) *Trends Cell. Biol.* 2(5):139-144 and WO94/02595, which are incorporated herein by reference for teachings relevant to such methods of delivery). For *in vivo* delivery, factors to consider in order to deliver a dsRNA agent molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue.

15 For administering a dsRNA agent systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases *in vivo*. Modification of the RNA or the pharmaceutical carrier or pharmaceutical excipient can also permit targeting of the dsRNA agent composition to the target tissue and avoid undesirable off-target effects. dsRNA agent molecules can be modified by chemical conjugation, *e.g.*, a carbohydrate conjugate as described above.

#### VI. Pharmaceutical Compositions

25 The present disclosure also includes pharmaceutical compositions and formulations that include the dsRNA agents of the present disclosure. In some embodiments, provided herein are pharmaceutical compositions containing a dsRNA agent, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the dsRNA agent are useful for treating a disease or disorder associated with the expression or activity of an HBV gene. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration *via* parenteral delivery, *e.g.*, by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery. In certain embodiments, the present disclosure provides compositions that are formulated for organ-specific (*e.g.*, hepatic) intra-arterial, intratumoral, intradermal,

35

intravitreal injection, ocular topical, ophthalmic (eye drops), nebulization, ocular topical or other topical routes, suppository, or oral administration. In preferred embodiments, compositions are administered subcutaneously.

The pharmaceutical compositions of the present disclosure may be administered  
5 in dosages sufficient to inhibit expression of an HBV gene. In some embodiments, a dsRNA agent will be administered at a dose of about 0.5 mg/kg to 50 mg/kg, or 0.3 mg/kg to 20 mg/kg, or 3 mg/kg to 10 mg/kg per dose, or preferably 3 mg/kg to 10 mg/kg per dose. For example, the dsRNA can be administered at about 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, or 50  
10 mg/kg per single dose. In some embodiments, a dsRNA agent is administered at a dose of 50 mg to 900 mg.

Compositions can also be prepared and packaged for a fixed dose to a subject independent of weight. Exemplary dosage levels can be calculated by multiplying the per kilogram body weight by the body weight for the average subject. For example, the  
15 average adult human is typically considered to be about 70 kg.

A repeat-dose regimen may include administration of a therapeutic amount of dsRNA agent on a regular basis, such as once a month, once every other month, or once every third month. In preferred embodiments, the dsRNA agent is administered no more frequently than once per month. After an initial treatment regimen, the treatments  
20 can be administered on a less frequent basis.

The pharmaceutical composition can be administered for an indefinite period of time, *e.g.*, in a subject with one or more signs or symptoms of HBV infection, *e.g.*, detectable HBV antigen or HBV DNA including HBV cccDNA. In some  
25 embodiments, treatment with the dsRNA agent is performed for a discrete or defined period of time and provides a functional cure.

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a  
30 therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and *in vivo* half-lives for the individual dsRNA agents encompassed by the present disclosure can be made using conventional methodologies or on the basis of *in vivo* testing using an appropriate animal model, as described elsewhere herein.

A. Excipients

A “pharmaceutical carrier” or “pharmaceutical excipient” is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. Such agents are well known in the art.

B. Other Components

The compositions of the present disclosure can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics, or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present disclosure, such as preservatives, antioxidants, and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present disclosure. The formulations can be sterilized and, if desired, mixed with auxiliary agents, *e.g.*, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, or buffers, and the like, which do not deleteriously interact with the nucleic acid(s) of the formulation.

In some embodiments, pharmaceutical compositions featured in the present disclosure include (a) one or more dsRNA agent compounds and (b) one or more agents that function by a non-RNAi mechanism and that are useful in treating a disorder HBV associated disorder. Examples of such agents include, but are not limited to, an anti-inflammatory agent, anti-steatosis agent, anti-viral, and anti-fibrosis agent.

In addition, other substances commonly used to protect the liver, such as silymarin, can also be used in conjunction with the dsRNA agents described herein. Other agents useful for treating liver diseases include telbivudine, entecavir, and protease inhibitors such as telaprevir and other disclosed, for example, in US2005/0148548, US2004/0167116, US2003/0144217, and US2004/0127488.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. In some embodiments, compounds that exhibit high therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the present disclosure lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary  
5 within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the present disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product  
10 of a target sequence (*e.g.*, achieving a decreased concentration of the polypeptide) that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

15 In addition to their administration, as discussed above, the dsRNA agents featured herein can be administered in combination with other known agents effective in treatment of HBV infection. In any event, the administering physician can adjust the amount and timing of dsRNA agent administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

## 20 VII. Methods

The present disclosure also provides methods of inhibiting expression of HBV in a cell. The methods include contacting a cell with a dsRNA agent, *e.g.*, a double stranded dsRNA agent, in an amount effective to inhibit expression of HBV in the cell, thereby inhibiting expression of HBV in the cell.

25 Contacting of a cell with a dsRNA agent, *e.g.*, a double stranded dsRNA agent, may be done *in vitro* or *in vivo*. Contacting a cell *in vivo* with the dsRNA agent includes contacting a cell or group of cells within a subject, *e.g.*, a human subject, with the dsRNA agent. Combinations of *in vitro* and *in vivo* methods of contacting a cell are also possible. Contacting a cell may be direct or indirect, as discussed above.

30 Furthermore, contacting a cell may be accomplished *via* a targeting ligand, including any ligand described herein or known in the art. In preferred embodiments, the targeting ligand is a carbohydrate moiety, *e.g.*, a GalNAc<sub>3</sub> ligand, or any other ligand that directs the dsRNA agent to a site of interest.

In some embodiments of the methods of the present disclosure, the dsRNA  
35 agent is administered to a subject such that the dsRNA agent is delivered to a specific

site within the subject. The inhibition of expression of an HBV gene may be assessed using measurements of the level or change in the level of HBV mRNA or HBV protein in a sample derived from fluid or tissue from the specific site within the subject. In preferred embodiments, the site is selected from liver and blood. The site may also be a subsection or subgroup of cells or fluid prepared from any one of the aforementioned sites.

In some embodiments, the methods disclosed herein are useful for treating a subject having an HBV infection, *e.g.*, a subject that would benefit from reduction in HBV gene expression or HBV replication. In one aspect, the present disclosure provides methods of reducing the level of Hepatitis B virus cccDNA in a subject infected with HBV. In another aspect, the present disclosure provides methods of reducing the level of HBV antigen, *e.g.*, HBsAg or HBeAg, in a subject infected with HBV. In another aspect, the present disclosure provides methods of reducing the viral load of HBV in a subject infected with HBV. The present disclosure also provides methods of reducing the level of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in a subject infected with HBV (although a transient elevation of ALT or AST can be associated with viral clearance). In one aspect, the present disclosure provides methods for increasing the level of anti-HBV antibodies in a subject infected with HBV. In another aspect, the present disclosure provides methods of treating a subject having an HBV infection. In one aspect, the present disclosure provides methods of treating a subject having an HBV-associated disease, *e.g.*, hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; or hepatocellular carcinoma. Furthermore, as HDV infection depends on obligatory helper functions provided by HBV for transmission, and subjects having an HBV infection may also have an HDV infection, in some embodiments the methods for treatment described herein are also useful for treating a subject having an HDV infection or an HDV-associated disorder, such as hepatitis B virus infection, chronic hepatitis B infection (CHB), chronic Hepatitis B infection (CHB), cirrhosis, liver failure, and hepatocellular carcinoma (HCC). In some embodiments, the treatment methods (and uses) of the present disclosure include administering to the subject, *e.g.*, a human, a therapeutically effective amount of a dsRNA agent of the present disclosure targeting an HBV gene or a pharmaceutical composition comprising a dsRNA agent of the present disclosure targeting an HBV gene.

In one aspect, the present disclosure provides methods of preventing at least one symptom in a subject having an HBV infection, *e.g.*, presence of serum or liver HBV

cccDNA; the presence of serum HBV DNA; the presence of serum or liver HBV antigen, *e.g.*, HBsAg or HBeAg; elevated ALT; elevated AST; the absence or low level of anti-HBV antibodies; a liver injury; cirrhosis; delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease;

5 hepatocellular carcinoma; serum sickness-like syndrome; anorexia; nausea; vomiting, low-grade fever; myalgia; fatigability; disordered gustatory acuity and smell sensations (aversion to food and cigarettes); right upper quadrant and epigastric pain (intermittent, mild to moderate); hepatic encephalopathy; somnolence; disturbances in sleep pattern; mental confusion; coma; ascites; gastrointestinal bleeding; coagulopathy; jaundice;

10 hepatomegaly (mildly enlarged, soft liver); splenomegaly; palmar erythema; spider nevi; muscle wasting; spider angiomas; vasculitis; variceal bleeding; peripheral edema; gynecomastia; testicular atrophy; abdominal collateral veins (caput medusa); ALT levels higher than AST levels; elevated gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) levels, not more than 3 times the ULN); slightly low

15 albumin levels; elevated serum iron levels; leukopenia (*i.e.*, granulocytopenia); lymphocytosis; increased erythrocyte sedimentation rate (ESR); shortened red blood cell survival; hemolysis; thrombocytopenia; a prolongation of the international normalized ratio (INR); presence of serum or liver HBsAg, HBeAg, Hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM); hepatitis B surface antibody (anti-HBs),

20 or hepatitis B e antibody (anti-HBe), or HBV DNA; increased bilirubin levels; hyperglobulinemia; the presence of tissue-nonspecific antibodies, such as anti-smooth muscle antibodies (ASMAs) or antinuclear antibodies (ANAs) (10-20%); the presence of tissue-specific antibodies, such as antibodies against the thyroid gland (10-20%); elevated levels of rheumatoid factor (RF); low platelet and white blood cell counts;

25 lobular, with degenerative and regenerative hepatocellular changes, and accompanying inflammation; or predominantly centrilobular necrosis, whether detectable or undetectable. The methods include administering to the subject a therapeutically effective amount of the dsRNA agent, *e.g.*, dsRNA, or pharmaceutical compositions comprising the dsRNA agent, thereby preventing at least one symptom in the subject

30 having a disorder that would benefit from reduction in HBV gene expression, such as a subject having an HBV infection or a subject having both an HBV and an HDV infection.

In another aspect, the present disclosure provides uses of a therapeutically effective amount of a dsRNA agent of the present disclosure for treating a subject, *e.g.*,

35 a subject that would benefit from a reduction or inhibition of HBV gene expression,

such as a subject having an HBV infection or a subject having both an HBV and an HDV infection.

In a further aspect, the present disclosure provides uses of a dsRNA agent, *e.g.*, a dsRNA, of the present disclosure targeting an HBV gene or pharmaceutical  
5 composition comprising a dsRNA agent targeting an HBV gene in the manufacture of a medicament for treating a subject, *e.g.*, a subject that would benefit from a reduction of HBV gene expression or HBV replication, such as a subject having an HBV infection or a subject having both an HBV and an HDV infection, and a subject having a disorder that would benefit from reduction in HBV gene expression, *e.g.*, a HBV-associated  
10 disease.

In another aspect, the present disclosure provides uses of a dsRNA agent as described herein, for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction or inhibition of HBV gene expression or HBV replication.

15 In a further aspect, the present disclosure provides uses of a dsRNA agent as described herein in the manufacture of a medicament for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction or inhibition of HBV gene expression or HBV replication, such as a HBV-associated disease.

20 In some embodiments, an dsRNA agent targeting HBV is administered to a subject having an HBV infection or both and HBV and an HDV infection, or an HBV-associated disease such that the expression of one or more HBV genes, HBV ccc DNA levels, HBV antigen levels, HBV viral load levels, ALT, or AST, *e.g.*, in a cell, tissue, blood or other tissue or fluid of the subject are reduced by, or normalized by, at least  
25 80%, 85%, 90%, 95%, 98% or more towards normal when the dsRNA agent is administered to the subject.

The methods and uses of the present disclosure include, in some embodiments, administering a composition described herein such that expression of the target HBV gene is decreased, such as for about 1 month. In some embodiments, expression of the  
30 target HBV gene is decreased for an extended duration, *e.g.*, at least two months, three months, or longer. In some embodiments, the methods and uses of the present disclosure include administering a composition described herein result in a functional cure.

35 Administration of the dsRNA according to the methods and uses described herein may result in a reduction of the severity, signs, symptoms, or markers of such diseases or disorders in a patient with an HBV infection or both and HBV and an HDV

infection, or HBV-associated disease. By “reduction” in this context is meant a clinically significant decrease in such level. The reduction can be, for example, at least 80%, 85%, 90%, 95%, or 98%, or to below the level of detection.

In some embodiments, the efficacy of the methods of the present disclosure can be monitored by detecting or monitoring a reduction in a symptom of an HBV-associated disease. These symptoms may be assessed *in vitro* or *in vivo* using any method known in the art.

Efficacy of treatment of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker, or any other measurable parameter appropriate for a given disease being treated. It is well within the ability of one skilled in the art to monitor efficacy of treatment by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of CHB may be assessed, for example, by periodic monitoring of viral load and transaminase levels. Comparison of the later readings with the initial readings provides a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment by measuring any one of such parameters, or any combination of parameters. In connection with the administration of a dsRNA agent targeting HBV or pharmaceutical composition thereof, “effective against” an HBV-associated disease indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating HBV infection or an HBV-associated disease and the related causes.

A treatment effect is evident when there is a clinically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 50% in a measurable parameter of disease, and preferably at least 70% or more can be indicative of effective treatment. Efficacy for a given dsRNA agent drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a sign or symptom is observed.

Administration of the dsRNA agent can reduce the presence of serum or liver HBV cccDNA, the presence of serum or liver HBV antigen, *e.g.*, HBsAg or HBeAg; or

normalize ALT levels, or AST levels, *e.g.*, in a cell, tissue, blood, urine, or other compartment of the patient by at least 70%, 75%, 80%, 85%, 90%, or 95%, or to below the level of detection of the assay, towards or to the upper level of normal for a laboratory value.

5 Administration of the dsRNA agent can make detectable or increase the presence of serum or liver anti-HBV antibodies, *e.g.*, anti- HBsAg antibodies, *e.g.*, in a cell, tissue, blood, or other compartment of the patient by at least 80%, 85%, 90%, 95%, or more; or to make antibodies detectable when none were detectable prior to treatment.

Owing to the inhibitory effects on HBV expression, in some embodiments, a  
10 composition according to the present disclosure or a pharmaceutical composition prepared therefrom can enhance the quality of life.

Subjects that would benefit from a reduction or inhibition of HBV gene expression are those having an HBV infection or an HBV-associated disease or disorder as described herein.

15 Treatment of a subject that would benefit from a reduction or inhibition of HBV gene expression includes therapeutic and prophylactic treatment.

The present disclosure further provides methods and uses of a dsRNA agent or a pharmaceutical composition thereof for treating a subject that would benefit from reduction or inhibition of HBV gene expression, *e.g.*, a subject having a HBV-  
20 associated disease, in combination with other pharmaceuticals or other therapeutic methods, *e.g.*, with known pharmaceuticals or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders.

For example, in some embodiments, a dsRNA agent targeting one or more HBV genes is administered in combination with, *e.g.*, an agent useful in treating an HBV-  
25 associated disease as described herein. For example, additional therapeutics and therapeutic methods suitable for treating a subject that would benefit from reduction in HBV expression, *e.g.*, a subject having a HBV-associated disease, include a dsRNA agent targeting a different portion of the HBV genome, an antiviral agent, a nucleotide analog, a nucleoside analog, a reverse transcriptase inhibitor (*e.g.*, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir), an immune stimulator (*e.g.*, pegylated interferon alfa 2a (PEG-IFN- $\alpha$ 2a), Interferon alfa-2b, a recombinant human interleukin-7, and a Toll-  
35 like receptor 7 (TLR7) agonist), a therapeutic vaccine (*e.g.*, GS-4774, DV-601, and TG1050), a viral entry inhibitor (*e.g.*, Myrcludex), an oligonucleotide that inhibits the

secretion or release of HbsAg (*e.g.*, REP 9AC), a capsid inhibitor (*e.g.*, Bay41-4109 and NVR-1221), a cccDNA inhibitor (*e.g.*, IHVR-25), or other therapeutic agents or procedures, *e.g.*, liver transplant or chemotherapy, for treating a HBV-associated disease, or a combination of any of the foregoing.

5           A subject administered a dsRNA agent of the present disclosure may further be administered with one or more other therapeutics that function by a non-RNAi mechanism and that are useful in treating an HBV infection. Exemplary therapeutics that may be used in a combination therapy of the present disclosure include immune modulators, which stimulate the immune system by, for example, enhancing T-cell  
10 helper activity, maturation of B lymphocytes, inhibiting T-cell suppressors, and enhancing HLA type I expression. Suitable immune modulators include interferons, which have a variety of properties that include antiviral, immunomodulatory, and antiproliferative effects.

For example, the current treatment for chronic hepatitis B is interferon therapy,  
15 which is administered to subjects who have a documented HBV infection for at least six months, elevated liver enzymes (AST and ALT), and an actively dividing virus in their blood (HBeAg, or HBV DNA positive tests). Interferon- $\alpha$  therapy produces a long-term, sustained remission of the disease in about 35% of those with chronic hepatitis B, with normalization of liver enzymes and loss of the three markers for an active infection  
20 (HBeAg, HBV DNA, and HBsAg). Subjects with an acute HBV infection, end stage cirrhosis, or other major medical problems are typically not treated with interferon.

In addition, interferon therapy for patients with HBV-related cirrhosis decreases significantly the hepatocellular carcinoma (HCC) rate, particularly in patients with a larger amount of serum HBV DNA. In patients with HBeAg-positive compensated  
25 cirrhosis, virological, and biochemical remission following interferon therapy is associated with improved survival. In patients with chronic HBV infection, the clearance of HBeAg after treatment with interferon- $\alpha$  is associated with improved clinical outcomes. The standard duration of therapy is considered 16 weeks. Patients who exhibit a low level of viral replication at the end of the standard regimen benefit  
30 most from prolonged treatment.

In some embodiments, the methods of the present disclosure include administering to a subject having an HBV infection or HBV-associated disease a reverse transcriptase inhibitor. In some embodiments, the methods of the present disclosure include administering to a subject having an HBV infection or HBV-associated disease a  
35 reverse transcriptase inhibitor and an immune stimulator.

The dsRNA agent and an additional therapeutic agent or treatment may be administered at the same time or in the same combination, *e.g.*, parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times or by another method known in the art or described herein.

5           The present disclosure also provides methods of using a dsRNA agent or a composition containing a dsRNA agent as described herein to reduce or inhibit HBV expression in a cell. In yet other aspects, use of a dsRNA agent or a composition comprising a dsRNA agent as described herein for the manufacture of a medicament for reducing or inhibiting HBV gene expression in a cell are provided. In still other  
10 aspects, the present disclosure provides a dsRNA agent or a composition comprising a dsRNA agent disclosed herein for use in reducing or inhibiting HBV replication in a cell. In yet other aspects, use of a dsRNA agent or a composition comprising a dsRNA agent disclosed herein for the manufacture of a medicament for reducing or inhibiting  
15 HBV replication in a cell are provided. The methods and uses include contacting the cell with a dsRNA agent, as disclosed herein and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene or inhibiting HBV replication in the cell.

In the aforementioned methods and uses, the cell may be contacted *in vitro* or *in vivo*, *i.e.*, the cell may be within a subject.

20           A cell suitable for treatment using the methods of as disclosed herein may be any cell that expresses an HBV gene, *e.g.*, a cell infected with HBV, a cell comprising an expression vector comprising an HBV genome or portion of an HBV gene, or a transgenic mouse expressing an HBV gene. A cell suitable for use in the methods and uses as disclosed herein may be a mammalian cell, *e.g.*, a primate cell (such as a human  
25 cell or a non-human primate cell, *e.g.*, a monkey cell or a chimpanzee cell) or a non-primate cell (such as a mouse cell, a rat cell, or other mammalian cell). In certain embodiments, the cell is a cell that can be infected by HBV. In certain embodiments, the cell is a human cell, *e.g.*, a human liver cell.

30           HBV gene expression may be inhibited in the cell by at least 80%, 85%, 90%, or 95%, or more, *e.g.*, to below the level of detection of the assay.

          HBV replication may be inhibited in the cell by at least 80%, 85%, 90%, or 95%, or more, *e.g.*, to below the level of detection of the assay.

35           The *in vivo* methods and uses as disclosed herein may include administering to a subject a composition containing a dsRNA agent, where the dsRNA agent includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the HBV gene of the mammal to be treated. When the organism to be treated is a human,

the composition can be administered by any means known in the art including, but not limited to subcutaneous, intravenous, or intramuscular administration. In some embodiments, the compositions are administered by subcutaneous injection. In some embodiments, the dsRNA agent is formulated to administer the entire dose as a single injection. In some embodiments, the present disclosure provides compositions that are formulated for organ-specific (*e.g.*, hepatic) intra-arterial, intratumoral, intradermal, intravitreal injection, ocular topical, ophthalmic (eye drops), nebulization, ocular topical or other topical routes, suppository, or oral administration.

In one aspect, the present disclosure also provides methods for inhibiting the expression of an HBV gene in a mammal, *e.g.*, a human. The present disclosure also provides a composition comprising a dsRNA agent that targets an HBV gene in a cell of a mammal for use in inhibiting expression of the HBV gene in the mammal. In another aspect, the present disclosure provides use of a dsRNA agent that targets an HBV gene in a cell of a mammal in the manufacture of a medicament for inhibiting expression of the HBV gene in the mammal.

The methods and uses include administering to the mammal, *e.g.*, a human, a composition comprising a dsRNA agent that targets an HBV gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the HBV gene, thereby inhibiting expression of the HBV gene in the mammal.

In certain embodiments, reduction in gene expression can be assessed in a peripheral blood sample of the dsRNA agent-administered subject by any methods known in the art, *e.g.*, qRT-PCR, described herein. Reduction in protein production can be assessed by any methods known in the art and by methods, *e.g.*, ELISA or western blotting, described herein. Clinically acceptable methods for determining gene and protein expression levels are used as appropriate. In certain embodiments, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in HBV gene or protein expression. In some other embodiments, a blood sample serves as the tissue material for monitoring the reduction in HBV gene or protein expression.

In some embodiments, verification of RISC mediated cleavage of target *in vivo* following administration of dsRNA agent is done by performing 5'-RACE or modifications of the protocol as known in the art (Lasham A *et al.*, (2010) *Nucleic Acid Res.*, 38 (3) p-e19) (Zimmermann *et al.* (2006) *Nature* 441: 111-4).

The invention is further illustrated by the following examples, which should not be construed as limiting.

## EXAMPLES

### EXAMPLE 1

#### DSRNA AGENT SYNTHESIS

##### Source of reagents

- 5           Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

##### dsRNA Agent Design

- 10           As described in WO/2016/077321, the selection of dsRNA designs targeting HBV was driven by two primary factors: a) potency, and b) the desire to employ agents with near-perfect matches and with greater than 90% fractional coverage of the large number of public HBV sequences of all known genotypes (A through H). The coordinates for the RNA agent selection were determined relative to the NCBI HBV reference genome sequence NC\_003977.1 (GenBank Accession No. GI:21326584 (SEQ ID NO:1)). A first set of RNA agents containing structure-activity modifications, including various 2'-O-methyl and 2'-fluoro substitution patterns, centered on two adjacent regions of the HBV genome coding for surface antigen (HbSAg) and the HBV polymerase, was designed, synthesized, and screened *in vitro*. A second set of agents targeting additional regions in the HBV genome, in particular positions 1581-1599 of SEQ ID NO:1, the region that codes for HbSAg, polymerase, and the X gene, was also designed, synthesized, and screened *in vitro*. Selected sequences were subjected to further chemical modification and testing. These duplex designs are provided in WO2016/077321 (the entire contents of which are incorporated herein by reference); a detailed list of unmodified HBV sense and antisense strand nucleotide sequences is provided in Tables 3, 6, 12, 22, and 25 in WO2016/077321, and a detailed list of modified HBV sense and antisense strand nucleotide sequences is provided in Tables 4, 7, 13, 23, and 26 in WO2016/077321. Results from the screening assays performed with those agents are also provided therein.

- 30           Those studies identified the duplex AD-66810 having an antisense strand with the modified nucleotide sequence 5'-usGfsugaAfgCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:13) and a sense strand with the modified nucleotide sequence 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29) wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-

methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively; Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively; and s is a phosphorothioate linkage; and wherein an N-acetylgalactosamine moiety N-

5 [tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol (also known as (Hyp-(GalNAc-alkyl)<sub>3</sub>) or referred to herein as L96) is covalently linked to the 3' end of the sense strand.

A further study provided herein was performed to identify potent and specific dsRNA agent molecules based on the previously identified sequence AD-66810,

10 targeting the X transcript of human hepatitis B virus (HBV; U95551). To achieve this objective, a series of chemically modified dsRNA agents were designed, synthesized, and tested for activity *in vitro* using a Dual-Luc reporter based assay and the HepG2.2.15 cell line. All compounds were conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand (L96) covalently linked to the 3' end of the

15 sense strand.

#### dsRNA Agent Synthesis

HBV sense and antisense strand sequences were synthesized at 1  $\mu$ mol scale on a Mermade 192 synthesizer (BioAutomation) using solid support mediated phosphoramidite chemistry. The solid support was controlled pore glass (500 Å)

20 loaded with custom GalNAc ligand or universal solid support (AM biochemical). Ancillary synthesis reagents, 2'-F and 2'-O-Methyl RNA, and deoxy phosphoramidites were obtained from Thermo-Fisher™ (Milwaukee, WI) and Hongene (China). 2'F 2'-O-Methyl, GNA (glycol nucleic acids), 5'-phosphate, and abasic modifications were introduced employing the corresponding phosphoramidites. Synthesis of 3' GalNAc

25 conjugated single strands was performed on a GalNAc modified CPG support. Custom CPG universal solid support was used for the synthesis of antisense single strands. Coupling time for all phosphoramidites (100 mM in acetonitrile) was 5 minutes employing 5-Ethylthio-1H-tetrazole (ETT) as activator (0.6 M in acetonitrile). Phosphorothioate linkages were generated using a 50 mM solution of 3-

30 ((Dimethylamino-methylidene) amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from Chemgenes (Wilmington, MA, USA)) in anhydrous acetonitrile/pyridine (1:1 v/v). Oxidation time was 3 minutes. All sequences were synthesized with final removal of the DMT group ("DMT off").

Upon completion of the solid phase synthesis, oligoribonucleotides were

35 cleaved from the solid support and deprotected in sealed 96 deep well plates using 200

5  $\mu$ L Aqueous Methylamine reagents at 60°C for 20 minutes. At the end of cleavage and deprotection step, the synthesis plate was allowed to come to room temperature and was precipitated by addition of 1mL of acetontile: ethanol mixture (9:1). The plates were cooled at -80°C for 2 hours, supernatant decanted carefully with the aid of a multi-  
 10 channel pipette. The oligonucleotide pellet was re-suspended in 20mM NaOAc buffer and was desalted using a 5 mL HiTrap™ size exclusion column (GE Healthcare™) on an AKTA Purifier System equipped with an A905 autosampler and a Frac 950 fraction collector. Desalted samples were collected in 96-well plates. Samples from each sequence were analyzed by LC-MS to confirm the identity, UV (260 nm) for  
 15 quantification, and a selected set of samples by IEX chromatography to determine purity.

15 Annealing of HBV single strands was performed on a Tecan liquid handling robot. Equimolar mixture of sense and antisense single strands were combined and annealed in 96-well plates. After combining the complementary single strands, the 96-  
 20 well plate was sealed tightly and heated in an oven at 100°C for 10 minutes and allowed to come slowly to room temperature over a period 2-3 hours. The concentration of each duplex was normalized to 10 $\mu$ M in 1X PBS.

20 Abbreviations for modified nucleotide monomers disclosed herein are shown in Table 1. Table 2 shows AD-66810 and the HBV dsRNA agents synthesized using the above methods.

Table 1. Abbreviations of nucleotide monomers used in modified nucleic acid sequence representation.

25 It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.

Abbreviation	Nucleotide(s)
A	adenosine-3'-phosphate
Af	2'-fluoroadenosine-3'-phosphate
Afs	2'-fluoroadenosine-3'-phosphorothioate
As	adenosine-3'-phosphorothioate
C	cytidine-3'-phosphate
Cf	2'-fluorocytidine-3'-phosphate
Cfs	2'-fluorocytidine-3'-phosphorothioate
Cs	cytidine-3'-phosphorothioate
G	guanosine-3'-phosphate

<b>Abbreviation</b>	<b>Nucleotide(s)</b>
Gf	2'-fluoroguanosine-3'-phosphate
Gfs	2'-fluoroguanosine-3'-phosphorothioate
Gs	guanosine-3'-phosphorothioate
T	5'-methyluridine-3'-phosphate
Tf	2'-fluoro-5-methyluridine-3'-phosphate
Tfs	2'-fluoro-5-methyluridine-3'-phosphorothioate
Ts	5-methyluridine-3'-phosphorothioate
U	uridine-3'-phosphate
Uf	2'-fluorouridine-3'-phosphate
Ufs	2'-fluorouridine -3'-phosphorothioate
Us	uridine -3'-phosphorothioate
a	2'-O-methyladenosine-3'-phosphate
as	2'-O-methyladenosine-3'- phosphorothioate
c	2'-O-methylcytidine-3'-phosphate
cs	2'-O-methylcytidine-3'- phosphorothioate
g	2'-O-methylguanosine-3'-phosphate
gs	2'-O-methylguanosine-3'- phosphorothioate
t	2'-O-methyl-5-methyluridine-3'-phosphate
ts	2'-O-methyl-5-methyluridine-3'-phosphorothioate
u	2'-O-methyluridine-3'-phosphate
us	2'-O-methyluridine-3'-phosphorothioate
s	phosphorothioate linkage
L96	N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol (or "Hyp-(GalNAc-alkyl) <sup>3</sup> ")
(Agn)	adenosine-glycol nucleic acid (GNA)
(Asn)	adenosine-serinol-nucleic acid (SNA)
(Gsn)	guanosine-serinol-nucleic acid (SNA)
dA	2'-deoxyadenosine-3'-phosphate
dAs	2'-deoxyadenosine-3'-phosphorothioate
dC	2'-deoxycytidine-3'-phosphate
dCs	2'-deoxycytidine-3'-phosphorothioate
dG	2'-deoxyguanosine-3'-phosphate
dGs	2'-deoxyguanosine-3'-phosphorothioate
dT	2'-deoxythymidine-3'-phosphate

Abbreviation	Nucleotide(s)
dTs	2'-deoxythymidine-3'-phosphorothioate
dU	2'-deoxyuridine
dUs	2'-deoxyuridine-3'-phosphorothioate

Table 2. Modified nucleotide sequences of GalNAc-conjugated HBV dsRNA agent

DuplexID	Sense Sequence (5' to 3')	SEQ ID	Antisense Sequence (5' to 3')	SEQ ID
AD-66810	gsusguGfcAfCfUfucguucacaL96	10	usGfsugaAfgCfGfaaguGfcAfcacsusu	13
AD-192282	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gCfGfaaguGfcAfdCacsusu	14
AD-192289	gsusgugcdAcdTucguucacaL96	11	usdGsuga(Asn)gcgaadGudGcacacsusu	15
AD-81890	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gCfGfaaguGfcAfcacsusu	16
AD-81892	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gcgaaguGfcAfcacsusu	17
AD-192290	gsusgugcdCdTucguucacaL96	12	usdGsuga(Asn)gcgaadGudGcacacsusu	15
AD-192283	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gcgaaguGfdCAfcacsusu	18
AD-192291	gsusgugcdAcdTucguucacaL96	11	usdGsugaa(Gsn)cgaadGudGcacacsusu	19
AD-192277	gsusguGfcAfCfUfucguucacaL96	10	usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu	20
AD-192284	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gcgaaguGfcAfdCacsusu	21
AD-192292	gsusgugcdCdTucguucacaL96	12	usdGsugaa(Gsn)cgaadGudGcacacsusu	19
AD-192285	gsusgugcdAcdTucguucacaL96	11	usdGsuga(Agn)gcgaadGudGcacacsusu	22
AD-192293	gsusguGfcAfCfUfucguucacaL96	10	usGfsudGadAgdCGfaaguGfcAfcacsusu	23
AD-192279	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu	24
AD-192286	gsusgugcdCdTucguucacaL96	12	usdGsuga(Agn)gcgaadGudGcacacsusu	22
AD-192294	gsusguGfcAfCfUfucguucacaL96	10	usGfsudGadAgdCGfaaguGfcAfdCacsusu	25
AD-192280	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gdCGfaaguGfcAfcacsusu	26
AD-192287	gsusgugcdAcdTucguucacaL96	11	usdGsuga(Agn)gcgaadGudGcdAcacsusu	27
AD-192281	gsusguGfcAfCfUfucguucacaL96	10	usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu	28
AD-192288	gsusgugcdCdTucguucacaL96	12	usdGsuga(Agn)gcgaadGudGcdAcacsusu	27

EXAMPLE 2

*IN VITRO* SCREENING OF DSRNA AGENT DUPLEXES

Dual-Glo® Luciferase assay:

- 5 Cos7 cells (ATCC®, Manassas, VA) were grown to near confluence at 37°C in an atmosphere of 5% CO<sub>2</sub> in DMEM (ATCC) supplemented with 10% FBS, before being released from the plate by trypsinization. Transfection of Cos7 cells with double

stranded agents and psiCHECK2-HBV (an expression vector comprising a nucleotide sequence encoding a portion of a consensus wild-type HBV sequence; SEQ ID NO:5), or double stranded agents and psiCHECK2 vectors expressing the nucleotide sequence of HBV genotype A, C, E, or F (SEQ ID NOs:6, 7, 8, or 9, respectively), were carried  
5 out by adding 5µl of RNA duplexes and 5µl of psiCHECK2-HBV (or psiCHECK2-HBV genotype A, C, E, or F) plasmid per well along with 5µl of Opti-MEM® plus 0.1µl of Lipofectamine™ RNAiMax per well (Invitrogen™, Carlsbad CA. cat # 13778-150) and then incubated at room temperature for 15 minutes. The mixture was then added to the cells, which were re-suspended in 35µl of fresh complete media. The  
10 transfected cells were incubated at 37°C in an atmosphere of 5% CO<sub>2</sub>.

Forty-eight hours after the dsRNA agents and psiCHECK2 plasmid were transfected; Firefly (transfection control) and Renilla (fused to HBV target sequence) luciferase were measured. First, media was removed from cells. Then Firefly luciferase activity was measured by adding 20µl of Dual-Glo® Luciferase Reagent  
15 equal to the culture medium volume to each well and mix. The mixture was incubated at room temperature for 30 minutes before luminescence (500nm) was measured on a Spectramax® (Molecular Devices) to detect the Firefly luciferase signal. Renilla luciferase activity was measured by adding 20µl of room temperature of Dual-Glo® Stop & Glo® Reagent was added to each well and the plates were incubated for 10-15  
20 minutes before luminescence was again measured to determine the Renilla luciferase signal. The Dual-Glo® Stop & Glo® Reagent, quenches the firefly luciferase signal and sustained luminescence for the Renilla luciferase reaction. dsRNA agent activity was determined by normalizing the Renilla (HBV) signal to the Firefly (control) signal within each well. The magnitude of dsRNA agent activity was then assessed relative to  
25 cells that were transfected with the same vector but were not treated with dsRNA agent or were treated with a non-targeting dsRNA agent. All transfections were done at n=2 or greater.

The results of these assays using the agents listed in Table 2 are provided in Table 3.

30 HepG2.2.15 and PLC *in vitro* Screening:

HepG2.2.15 and PLC (human hepatoma cells; ATCC® CRL-8024) cells were grown to near confluence at 37°C in an atmosphere of 5% CO<sub>2</sub> in DMEM or EMEM medium (ATCC) supplemented, respectively, with 10% FBS (ATCC) before being released from the plate by trypsinization. Reverse transfection was carried out by  
35 adding 5µl of dsRNA agent duplexes per well into a 96-well plate along with 14.8µl of

Opti-MEM® plus 0.2µl of Lipofectamine™ RNAiMax per well (Invitrogen™, Carlsbad CA. cat # 13778-150) and incubated at room temperature for 15 minutes. Eighty micro liters of complete growth media without antibiotic containing  $2 \times 10^4$  HepG2.2.15 or PLC cells were then added. Cells were incubated for 24, 48, and 72  
5 hours prior to RNA purification.

The results of these assays using the agents listed in Table 2 are provided in Table 4.

Total RNA isolation using MagMAX-96 Total RNA Isolation Kit (Applied Biosystem, Forer City CA, part #: AM1830):

10 Cells were harvested and lysed in 140µl of Lysis/Binding Solution then mixed for 1 minute at 850rpm using an Eppendorf™ Thermomixer (the mixing speed was the same throughout the process). Twenty microliters of magnetic beads and Lysis/Binding Enhancer mixture were added into cell-lysate and mixed for 5 minutes. Magnetic beads were captured using magnetic stand and the supernatant was removed without  
15 disturbing the beads. After removing supernatant, magnetic beads were washed with Wash Solution 1 (isopropanol added) and mixed for 1 minute. Beads were captured again and supernatant removed. Beads were then washed with 150µl Wash Solution 2 (Ethanol added), captured and supernatant was removed. Fifty µl of DNase mixture (MagMax turbo DNase Buffer and Turbo DNase) was then added to the beads and they  
20 were mixed for 10 to 15 minutes. After mixing, 100µl of RNA Rebinding Solution was added and mixed for 3 minutes. Supernatant was removed and magnetic beads were washed again with 150µl Wash Solution 2 and mixed for 1 minute and supernatant was removed completely. The magnetic beads were mixed for 2 minutes to dry before RNA was eluted with 50µl of water.

25 cDNA synthesis using ABI High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, Cat #4368813):

A master mix of 2µl 10X Buffer, 0.8µl 25X dNTPs, 2µl Random primers, 1µl Reverse Transcriptase, 1µl RNase inhibitor and 3.2µl of H<sub>2</sub>O per reaction was added into 10µl total RNA. cDNA was generated using a Bio-Rad® C-1000 or S-1000  
30 thermal cycler (Hercules, CA) through the following steps: 25°C 10 min, 37°C 120 min, 85°C 5 sec, 4°C hold.

Real time PCR:

Two µl of cDNA were added to a master mix containing 0.5µl of human GAPDH TaqMan Probe (Applied Biosystems Cat # 4319413E), 1µl SORF2 specific TaqMan® probe and 5µl Lightcycler 480 probe master mix (Roche Cat # 04887301001) per well in a 384 well plates (Roche cat # 04887301001). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche) using the DDCt(RQ) assay. To calculate relative fold change, real time data were analyzed using the DDCt method and normalized to assays performed with cells transfected with AD-1955, or mock transfected cells.

To calculate relative fold change, real time data were analyzed using the DDCt method and normalized to assays performed with cells transfected with a non-targeting control dsRNA agent.

EXAMPLE 3

TRANSFECTION OF GALNAC CONJUGATED HBV-TARGETING DSRNA AGENTS IN DUAL-LUC SYSTEM

Silencing of HBV mRNA following transfection with each of the conjugated dsRNA agents is shown in Table 3. Each dsRNA agent was tested by transfection in Cos7 cells at dsRNA agent concentrations of 50nM, 10nM, and 0.1nM. Based on the screening results, 7 out of the 20 dsRNA agents demonstrated comparable potency to the AD-66810 parent.

Table 3. Screening Results using Dual-Luc assay of Conjugated HBV dsRNA agents Transfected at 50nM, 10nM, or 1nM

Duplex ID	Mean ± SD HBV dsRNA agent Message Remaining (%) <sup>a</sup>		
	50 nM	10 nM	0.1 nM
AD-66810	43.18 ± 5.33	43.83 ± 3.07	108.98 ± 13.64
AD-192282	51.82 ± 2.45	58.09 ± 12.10	121.63 ± 7.49
AD-192289	71.82 ± 12.28	84.84 ± 6.00	115.35 ± 16.01
AD-81890	47.09 ± 3.36	53.70 ± 7.58	112.10 ± 15.95
AD-81892	62.70 ± 1.42	55.04 ± 6.21	107.79 ± 14.23
AD-192290	78.23 ± 5.63	77.77 ± 6.00	98.24 ± 4.13
AD-192283	54.62 ± 3.97	46.70 ± 9.86	113.80 ± 21.17
AD-192291	73.97 ± 6.80	64.32 ± 5.52	111.71 ± 10.18
AD-192277	43.08 ± 1.58	34.82 ± 4.23	103.32 ± 12.95

Duplex ID	Mean $\pm$ SD HBV dsRNA agent Message Remaining (%) <sup>a</sup>		
	50 nM	10 nM	0.1 nM
AD-192284	70.20 $\pm$ 5.87	54.10 $\pm$ 3.08	119.01 $\pm$ 12.73
AD-192292	70.91 $\pm$ 13.89	65.99 $\pm$ 3.57	102.58 $\pm$ 8.12
AD-192285	86.15 $\pm$ 7.45	91.39 $\pm$ 8.92	116.62 $\pm$ 8.93
AD-192293	48.05 $\pm$ 0.45	46.38 $\pm$ 6.26	120.84 $\pm$ 10.62
AD-192279	51.29 $\pm$ 6.93	38.35 $\pm$ 2.50	114.22 $\pm$ 10.41
AD-192286	89.16 $\pm$ 12.87	88.74 $\pm$ 4.44	118.16 $\pm$ 12.97
AD-192294	54.36 $\pm$ 5.03	41.89 $\pm$ 5.61	114.19 $\pm$ 11.55
AD-192280	49.20 $\pm$ 7.13	57.22 $\pm$ 14.47	116.35 $\pm$ 6.87
AD-192287	81.73 $\pm$ 14.38	84.10 $\pm$ 10.24	127.11 $\pm$ 12.61
AD-192281	38.74 $\pm$ 4.01	38.45 $\pm$ 4.54	120.99 $\pm$ 7.00
AD-192288	85.37 $\pm$ 9.30	86.14 $\pm$ 5.32	118.09 $\pm$ 9.30

Abbreviations: ID=identification; SD=standard deviation

<sup>a</sup> Fraction of remaining relative HBV expression (versus control transfected cells) 48 hours after transfection of screening set of HBV dsRNA agents.

#### EXAMPLE 4

##### TRANSFECTION OF GALNAC CONJUGATED HBV-TARGETING DSRNA AGENTS IN HEPG2.2.15 CELLS

Silencing of HBV mRNA (PORF1 and SORF2 mRNA as determined using forward and reverse primers and a TaqMan probe) in HepG2.2.15 cells following transfection with each of the conjugated dsRNA agents is shown in Table 4. Overall, more robust silencing of PORF1 and SORF2 viral transcripts was observed in HepG2.2.15 cells compared to the silencing observed in the Dual-Luc overexpression system, with 10 dsRNA agents having had comparable potency to the parent molecule AD-66810 parent. Similar dsRNA agent activity was observed for against PORF1 and SORF2 mRNAs, which was expected since dsRNA agent target sites are present in both transcripts.

Table 4. Screening Results using HepG2.2.15 of Conjugated HBV dsRNA agents  
Transfected at 50nM, 10nM, or 1nM

DuplexID	% Remain PORF1 (10nM) <sup>a</sup>	SD	% Remain PORF1 (0.1nM) <sup>a</sup>	SD	% Remain SORF2 (10nM) <sup>a</sup>	SD	% Remain SORF2 (0.1nM) <sup>a</sup>	SD
AD-66810	22.9	0.2	114.3	22.4	22.2	0.3	110.0	19.3
AD-192282	29.7	2.2	84.9	1.2	28.5	1.3	79.9	1.6

DuplexID	% Remain PORF1 (10nM) <sup>a</sup>	SD	% Remain PORF1 (0.1nM) <sup>a</sup>	SD	% Remain SORF2 (10nM) <sup>a</sup>	SD	% Remain SORF2 (0.1nM) <sup>a</sup>	SD
AD-192289	71.1	13.7	83.8	9.9	72.7	16.2	92.1	10.8
AD-81890	34.2	7.1	85.5	19.6	33.7	9.1	93.4	26.6
AD-81892	32.9	0.1	82.2	8.5	28.1	2.6	79.9	9.0
AD-192290	72.9	19.3	86.0	7.6	63.3	9.2	92.9	12.7
AD-192283	38.7	18.5	82.0	18.7	31.0	14.5	80.2	12.9
AD-192291	62.9	16.1	80.2	17.6	54.0	13.3	86.2	20.1
AD-192277	33.9	15.4	74.2	17.4	29.0	11.9	76.9	15.7
AD-192284	33.4	8.5	82.4	6.5	25.9	8.2	78.6	2.7
AD-192292	52.2	5.3	80.1	0.9	47.1	6.2	84.4	7.8
AD-192285	85.5	1.0	85.8	10.6	73.1	8.5	84.8	2.9
AD-192293	26.9	1.8	79.1	21.9	24.0	1.7	79.7	16.3
AD-192279	27.2	4.5	81.0	11.1	22.7	4.7	77.8	13.7
AD-192286	91.6	2.5	92.4	5.8	80.3	4.7	93.1	4.6
AD-192294	25.7	2.1	78.2	4.3	23.1	1.5	78.6	10.8
AD-192280	39.7	11.8	83.9	20.8	30.1	8.6	83.0	8.9
AD-192287	66.1	1.2	81.1	7.5	59.3	6.3	80.9	7.5
AD-192281	28.1	8.0	79.6	11.3	23.2	5.2	78.9	4.6
AD-192288	73.1	0.2	95.4	14.5	62.5	7.6	104.4	13.3

Abbreviations: SD=standard deviation

<sup>a</sup> Fraction of remaining relative HBV expression (versus control transfected cells) 24 hours after transfection of screening set of HBV dsRNA agents.

Based on the above studies, duplex AD-81890 was selected for further analysis.

#### EXAMPLE 5

##### EVALUATION OF AD-81890 PHARMACOLOGY IN AN ADENO-ASSOCIATED HBV MOUSE MODEL FOLLOWING A SINGLE SUBCUTANEOUS INJECTION

5

Pharmacology of AD-81890 was assayed in an adeno-associated HBV (HBV-AAV) mouse model. AAV8-HBV (SignaGen Laboratories) was diluted in 1 × PBS to a final concentration of 2 × 10<sup>12</sup> GC/mL. Male C57BL/6 mice 6-8 weeks of age were injected intravenously *via* lateral tail vein with 2 × 10<sup>11</sup> GC/mouse in a fixed volume of 100 μL.

10

AD-81890 was diluted with sterile 1× PBS and administered with a variable volume of 10μl/g. Animals received a single SC dose of AD-81890 at 0.3, 1, or 3 mg/kg, and blood was collected at Day -24, -2, 0, 14, 21, 33, 47, 59, and 74 post dose *via* retroorbital sinus as described in Table 5.

Table 5. AD-81890 Single Dose AAV-HBV Study Design

Group	Compound	Dose on Day 0 (mg/kg)	No. of Animals	Serum Collection Time Points
1	PBS	0	9	Days -24, -2, 0, 14, 21, 33, 47, 59, 74
2	AD-81890	0.3	9 <sup>a</sup>	
3		1	9	
4		3	9	

Abbreviations: No.=number; PBS=phosphate buffered saline

<sup>a</sup> n=8 animals on Day 47; n=6 on Day 59; n=5 on Day 72, animals euthanized due to fight wounds

After collection, blood was allowed to clot for 30 minutes and was then spun in a microcentrifuge for 10 min at 13,000 rpm and 4°C. Serum was aspirated and stored at  
5 -20°C.

Hepatitis B Virus surface antigen protein levels were evaluated via ELISA (BioTang, Waltham, MA). The US Biologics (Memphis, TN) HBsAg protein was used to generate the standard curve. Serum samples were diluted at 1× PBS (Gibco, Gaithersburg, MD) at 1:2000 or 1:500 and evaluated using the ELISA protocol with  
10 minor modifications. Briefly, 50 µL/well of diluted serum or standard were loaded into the plate and incubated for 1 h at 37°C. After this incubation, 50 µL /well enzyme conjugate was added to each well, and the plate was incubated at 37°C for 30 min. The plate was washed with 3 times 300 µL/well 1× wash buffer, then blotted until all liquid was removed from the wells, 100 µL/well substrate was added, and plates were  
15 incubated at 37°C for 30 min. Finally, an additional 100 µL/well of stop solution was added and absorbance was measured at a wavelength of 450 nm. In any instance where calculated HBsAg level fell below the lower limit of quantitation (LLOQ) of the assay, values were recorded as the LLOQ (*i.e.*, 313 ng/mL).

Mean ± SD serum HBsAg concentrations in HBV-AAV mice following a single  
20 subcutaneous (SC) dose of AD-81890 are shown in Figure 2A. Mean ± SD serum HBsAg levels in HBV-AAV mice relative to baseline are shown in Figure 2B. A single SC injection of AD-81890 at 0.3, 1, or 3 mg/kg led to potent and sustained reduction of serum HBsAg concentrations in HBV-AAV mice, with a maximum reduction of 92% observed on Day 7 in the highest (3mg/kg) AD-81890 dose group. The maximum level  
25 of reduction was maintained in the highest dose group through Day 33 after which HBsAg levels began returning towards baseline (Figure 2B). Intermediate reductions in serum HBsAg concentrations were observed in the 0.3mg/kg and 1mg/kg AD081890 dose groups with a maximum reduction on Day 7 of 23% and 72%, respectively.

HBsAg levels in both the 0.3mg/kg and 1mg/kg AD-81890 dose groups returned to baseline levels by study completion (Day 74).

#### EXAMPLE 6

##### EVALUATION OF AD-81890 PHARMACOLOGY IN AN ADENO-ASSOCIATED HBV MOUSE MODEL FOLLOWING MULTIPLE SUBCUTANEOUS INJECTIONS

Pharmacology of AD-81890 was assayed in an adeno-associated HBV (HBV-AAV) mouse model. AAV8-HBV (SignaGen Laboratories) was diluted in 1 × PBS to a final concentration of  $2 \times 10^{12}$  GC/mL. Male C57BL/6 mice 6-8 weeks of age were injected intravenously *via* lateral tail vein with  $2 \times 10^{11}$  GC/mouse in a fixed volume of 100 μL.

Each AD-66810 and AD-81890 were diluted with sterile 1X DPBS and administered with a variable volume of 10ul/g. Animals received AD-66810 at 1 mg/kg given Q2Wx6, or a single dose of AD-81890 at 9mg/kg, or multiple doses of AD-81890 at 1 or 3mg/kg given Q2Wx6 or QMx3. Serum was collected from animals at multiple timepoints as described in Table 6. Blood was collected *via* retroorbital sinus as described in Table 6.

Table 6. AD-81890 Multiple Dose AAV-HBV Study Design

Group	Compound	Dose on Day 0 (mg/kg)	Regimen	N=	Serum Collections
1	PBS	0	Q2Wx6	6	Day -55, -27, -13, 0, 14, 28, 42, 56, 70, 84, 98, 111, 126
2	AD-66810	1	Q2Wx6	6	
3	AD-81890	1	Q2Wx6	6	
4			QMx3	6	
5		3	Q2Wx6	6	
6			QMx3	6	
7		9	QMx1	6	

Blood samples were processed and ELISA assays were performed as described in the prior example. Results are shown in Table 7 below. Results with standard deviations are shown in Figure 3.

Table 7. AD-81890 Multiple Dose AAV-HBV Results Expressed as Average Log-fold Change

dsRNA agent	mg/kg	Regimen	Days													
			-55	-27	-13	0	14	28	42	56	70	84	98	111	125	140
PBS	-	Q2Wx6	-0.04	-0.09	-0.05	0.00	0.06	-0.01	-0.11	-0.03	0.03	0.00	-0.03	-0.01	0.04	0.00
AD-66810	1	Q2Wx6	0.02	-0.05	0.00	0.00	-0.74	-0.77	-1.41	-1.84	-1.91	-2.12	-1.78	-1.29	0.97	-0.81
	1	Q2Wx6	0.02	-0.04	0.06	0.00	-0.59	-0.76	-0.89	-1.02	-1.13	-1.23	-0.95	-0.95	0.39	-0.13
	1	QMx3	0.06	0.01	0.06	0.00	-0.51	-0.32	-0.73	-0.51	-0.79	-0.63	-0.45	-0.20	0.11	0.09
AD-81890	3	Q2Wx6	0.03	-0.04	0.02	0.00	-1.30	-1.73	-2.49	-2.57	-2.61	-2.77	-2.03	-1.59	1.16	-0.53
	3	QMx3	-0.02	0.00	0.03	0.00	-1.30	-1.06	-1.56	-1.32	-1.75	-1.53	-1.15	-0.75	0.38	-0.30
	9	QMx1	0.06	-0.03	0.00	0.00	-2.71	-2.60	-2.03	-1.16	-0.81	-0.45	-0.29	-0.07	0.04	-0.01

Dose responsive serum HBsAg level was observed in the AAV8-HBV mouse model after AD-81890 administration. A maximum HBsAg reduction of about 2.7 log<sub>10</sub> was observed after a single 9mg/kg dose or 3mg/kg q2w x 6 of AD-81890. Animals receiving 3mg/kg q2w x 6 had sustained HBsAg reduction of greater than 2 log<sub>10</sub> for a total of approximately 8 weeks.

These *in vivo* studies demonstrate that AD-81890 is effective in reducing HBsAg in serum in the HBV-AAV mouse model.

#### EXAMPLE 7

##### SPECIFIC OFF-TARGET ANALYSIS OF AD-81890

A combination of *in silico* bioinformatics methods and *in vitro* methods were used to assess potential off-target activity of the antisense strand of AD-81890.

##### Bioinformatics

A set of dsRNA agents targeting the 'X' gene of the Hepatitis B virus (HBV) subtype ayw (GenBank nucleotide ID U95551; NCBI GeneID: 7276; SEQ ID NO:49) were designed using custom R and Python scripts. The circular U95551 HBV genome has a length of 3182 bases and the 'X' gene CDS region is coded in the NCBI record in the positions 1376-1840. Details of the dsRNA agent design and screening method are provided above and in WO2016/077321.

##### Transfection Screen of GalNAc-conjugated dsRNA agents for off-target detection in

##### HepG2.2.15 cells

To measure off-target inhibition, the response of endogenously expressed transcripts by qPCR was tested in the hepatocyte cell line HepG2.2.15. Cells were transfected in 96-well plates (2 x 10<sup>4</sup> cells per well) with AD-81890 at a range of concentrations from 50nM to 5 fM using Lipofectamine RNAiMax (ThermoFisher). After 24 hours, RNA was extracted from cells using MagMAX™-96 Total RNA Isolation Kit (ThermoFisher); and cDNA was generated using the ABI High Capacity cDNA reverse transfection kit (ThermoFisher). Samples were assayed for inhibition of HBV mRNA and potential off-target silencing. For quantification by qPCR, HBV expression was assessed using two different custom TaqMan assays, PORF-1 and SORF-2, which recognize different regions of HBV viral transcripts.

To assess off-target silencing, TaqMan probes specific to each potential off-target (Table 8) were used for quantification. qPCR was performed with a LightCycler 480 Real-Time PCR machine (Roche).

Table 8. Potential Off-Target Sequences of AD-81890

Off-Target ID	Off-target Score	Mismatch Position <sup>a</sup>	Accession <sup>b</sup>	Target Gene
AD-81890_(Off-1)	3	19, 16, 13	NM_001040455.1	SIDT2
AD-81890_(Off-2)	3.4	14,11,10	NM_020861.1	ZBTB2

<sup>a</sup> Mismatch positions are defined with respect to the antisense strand in the 5'-3' direction, therefore, position 1 corresponds to the base complementary to the 5'-most nucleotide of the antisense strand of AD-81890

5 <sup>b</sup> In case where multiple RefSeq IDs are associated with the same target gene and off-target profile, both IDs are listed.

To determine the extent of on-target (HBV) and potential off-target gene inhibition, relative RNA levels were determined by normalization to human GAPDH RNA expression from the same sample. Results were compared to transfected nonspecific dsRNA agent controls and error is expressed as standard deviation. IC<sub>50</sub> of AD-81890 was 0.803 nM against the PORF1 transcript target and 0.766 nM against the SORF2 transcript target. No significant target knockdown was observed against the SIDT2 and ZBTB2 transcripts even at the highest concentration of AD-81890.

15 The extent of off-target inhibition by AD-81890 was assessed in dose response screens for the 2 potential off-targets from endogenously expressed transcripts in HepG2.2.15. AD-81890 did not inhibit expression for SIDT2 or ZBTB2 at any of the doses tested, while HBV inhibition was dose responsive. Fitting the dose-response data using a four-parameter fit model (XLfit) results in an IC<sub>50</sub>s of 803 pM and 766 pM for  
20 PORF-1 or SORF-2, respectively.

#### EXAMPLE 8

##### IN VITRO ANALYSIS OF AD-81890 SPECIFICITY USING RNA-SEQ IN HEPG2.2.15 CELLS

The impact of dsRNA agent chemistry modification by comparing AD-66810 and AD-81890 in the HBV-expressing HepG2.2.15 cell line was measured using transcriptome-wide changes in expression levels with RNA-Seq. The AD-66810 and  
25 AD-81890 molecules have the same nucleotide sequence but differ by the substitution of a single glycol nucleic acid (GNA) at position 6 from the 5' end of molecule of antisense strand (*see* Table 2).

HepG2.2.15 cells, a HepG2 derived cell line stably transfected with full genome  
30 HBV, were diluted with culture media to a final concentration of 187,500 cells/mL,

and 80  $\mu$ L was pipetted into 96-well collagen coated plates (BD Biocoat, Cat#356407) to give a final concentration of 15,000 cells/well.

dsRNA agent stocks were diluted in 1X DPBS to the following concentrations: 1,000 nM or 100 nM. RNAiMAX (ThermoFisher, Cat#13778150) was diluted with  
5 Opti-MEM (ThermoFisher Cat#31985062) at a concentration of 0.3  $\mu$ L RNAiMAX/10  $\mu$ L Opti-MEM and incubated for 5 minutes at room temperature. After incubation, 10  $\mu$ L/well was added to each well of 96-well collagen coated plates (BD Biocoat, Cat#356407), along with 10  $\mu$ L/well of the appropriate dsRNA agent dilution, mixed  
10 gently and incubated for 20 minutes at room temperature. 80  $\mu$ L of prepared cell suspension was added to each well to give final cell density of 15,000 cells/well and final dsRNA agent concentrations of 100 nM and 10 nM. Cells were incubated in a 37°C incubator with 5% CO<sub>2</sub> for 16-22 hours. Cells were plated such that each experimental condition had 16 wells and the experiment was performed two times.

The ThermoFisher RNAqueous-96 Total RNA Isolation Kit was used to isolate  
15 RNA as per the protocol. Briefly, after 16-22 hours, the supernatant was aspirated from each well, 100  $\mu$ L/well 1X DPBS was added to rinse away remaining media, then aspirated. 200  $\mu$ L of Lysis/Binding Solution was added to each well in row 1 and row 5 of each plate, pipetted up and down several times, and transferred to the subsequent row such that 4 wells/condition were pooled to ensure adequate RNA recovery. This  
20 resulted in four replicates per condition. 100  $\mu$ L 100% ethanol was added to each well of the culture plate containing lysates, mixed several times and transferred to the wells of the filter plate. Through a series of centrifugation steps (1,900xg, 1 minute) samples were washed with the provided wash solution, treated with DNase reagents, and eluted into 100  $\mu$ L nuclease-free water. RNA concentration was determined with the  
25 NanoDrop 8000 Spectrophotometer (ThermoFisher).

RNA was further treated with TURBO DNase (Ambion). Each RNA sample ( $\leq$ 10  $\mu$ g RNA/sample) was mixed with 2  $\mu$ L DNase, 10  $\mu$ L 10X buffer, and nuclease free water to a total volume of 100  $\mu$ L, then incubated at 37°C for 30 minutes. After DNase treatment, RNA was further purified with the RNeasy MinElute Cleanup Kit  
30 (Qiagen) as per the protocol. RNA was eluted in 30  $\mu$ L nuclease free water, and the RNA concentration was determined with the NanoDrop 8000 Spectrophotometer. RNA was stored at -80°C. This RNA was subsequently used for cDNA library preparation with the TruSeq Stranded Total RNA Library Prep Kit (Illumina) and sequenced on the NextSeq500 desktop sequencer (Illumina), all according to manufacturers' instructions.  
35 Two experimental repeats were performed.

HepG2.2.15 cells were transfected in quadruplicate with 10 or 100 nM of AD-66810 or AD-81890 and cultured alongside untreated controls for 24 h. RNA extracted with the Purelink RNA kit (ThermoFisher) was used for cDNA library preparation with the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero Human/Mouse/Rat for rRNA depletion (Illumina) and sequenced on the NextSeq500 desktop sequencer (Illumina), all according to manufacturers' instructions. A total of 40 samples were pooled per NextSeq 500/550 High Output v2 (75 cycles) flow cell (Illumina). Two experimental repeats were performed.

Raw RNA-Seq reads were filtered with minimal mean quality scores of 25 and minimal remaining length of 36, using fastq-mcf. Filtered reads were simultaneously aligned to the Human (hg19/GRCh37) and HBV (GenBank nucleotide ID U95551; NCBI GeneID: 7276) genomes using STAR (version 2.4.2a). Due to the circular structure of the HBV genome, 46 base pairs were repeated at the end of a linearized version of the HBV sequence to allow for reads to map at the break point. Uniquely aligned reads mapping to exons were counted by featureCounts (version 1.5.0). All samples had >5M mapped reads. Differential gene expression analysis was performed in R (version 3.4.1) using the package DESeq2 (version 1.16.1). Multiple Testing Correction to obtain adjusted p-values was performed by DESeq2 using the method of Benjamini & Hochberg, 1995.

MA plots were used to visualize both on-target HBV knockdown and off-target effects. The analysis of GNA chemistry in mitigating global off-target effects was limited to downregulated genes ( $\log_2$  Fold Change < 0). Upregulated genes ( $\log_2$  Fold Change > 0) were considered secondary effects. Assessment of off-target effects was limited to the lowest (10 nM) dose since near maximal HBV knockdown was attained. To compare transcriptomic noise, genes that were significantly downregulated (adjusted p-value < 0.05) were identified in AD-66810 and/or AD-81890. The extent of downregulation was visualized by a boxplot of  $\log_2$  Fold Change (Figure 4), with statistical differences between AD-66810 and AD-81890 assessed using Welch's two-sided, two-sample *t*-test (Table 9).

Table 9. Statistical Testing of Significantly Downregulated Genes

exp	dose	mean.AD-66810.IFC	mean.AD-81890.IFC	t.statistic	p.value	d.o.f.	N
1	10nM	-0.353	-0.171	-16.1	3.14E-52	1003	523
1	100nM	-0.350	-0.102	-25.6	7.35E-	1743	908

					123		
2	10nM	-0.334	-0.154	-13.4	5.28E-37	757	391
2	100nM	-0.314	-0.179	-13.1	1.35E-37	1693	858

exp: experimental repeat; Mean.AD-66810.IFC: Average log<sub>2</sub> Fold Change of significantly downregulated genes in AD-66810 and/or AD-81890; Mean.AD-81890.IFC: Average log<sub>2</sub> Fold Change of significantly downregulated genes in AD-81890 and/or AD-66810; t.statistic: *t*-statistic from Welch's two-sided, two-sample *t*-test; p.value: p-value from Welch's two-sided, two-sample *t*-test; d.o.f.: degrees of freedom; N: Number of genes significantly downregulated (p<0.05) in AD-66810 and/or AD-81890

Consistent reduction in the off-target effect with AD-81890 as compared to AD-66810 was observed across both experimental repeats (Figure 4, Table 9). At 10nM, AD-81890 showed a 52% (repeat 1) or 54% reduction (repeat 2) in the average log<sub>2</sub> Fold Change of the significantly downregulated genes as compared to AD-66810 (Table 9). At 100nM, AD-81890 showed a 71% (repeat 1) or 43% reduction (repeat 2) in average log<sub>2</sub> Fold Change as compared to AD-66810 (Table 9). In all cases, the observed reduction in log<sub>2</sub> Fold Change was highly statistically significant. Therefore, AD-81890 had substantially lower levels of transcriptomic noise.

10

## EXAMPLE 9

## EVALUATION OF HUMAN-SPECIFIC HEPATOTOXICITY IN PXB-MICE

The PXB-mouse is a chimeric mouse with a humanized liver that is highly repopulated by human hepatocytes (PhoenixBio). The mouse is a urokinase-type plasminogen activator (uPA)/severe combined immunodeficiency (SCID) mice transplanted with human hepatocytes (humanized liver uPA/SCID mice) (Mercer *et al.*, Nat. Med. 7:927-933, 2001). The reported humanized liver uPA/SCID mice has a replacement index (RI), the percent of human hepatocytes in the liver, of more than 70%. The mice can be used as a model for prediction of human drug metabolism, pharmacokinetics, and hepatotoxicity (Naritomi *et al.*, Drug Metab Pharmacokinet. 33:31-39, 2018).

A study was performed in PBX-mice to compare hepatotoxicity of AD-66810 and AD-81890. Mice were dosed on Days 0, 21, 28, 35, and 42 with 12, 36, or 100 mg/kg of AD-66810, AD-81890, or PBS (control) by subcutaneous injection (n=4 per group). General condition observations and body weight measurement was performed twice per week through Day 49. Blood was collected by retro-orbital bleed twice

weekly and serum was prepared using routine methods. A terminal bleed was performed, and animals were sacrificed by cardiac puncture and exsanguination. Necropsy was performed after exsanguination. The liver was harvested and weighed. Livers were divided for storage in RNAlater solution (Ambion), in formalin prior to paraffin embedding, and snap frozen.

All animals maintained body weight of more than 80% of the initial levels throughout the study period. In addition, the lowest arithmetic mean values of body weights in the compound-treated groups were higher than the control PBS-treated group.

Human serum albumin levels in blood were monitored throughout the course of the study. All surviving animals maintained blood h-Alb concentration of more than 7.0 mg/ml during the in-life phase of the study.

Liver enzymes were monitored throughout the course of the study. Specifically ALT, AST, ALP, GGT, TBIL, and TG were monitored throughout the study. The enzyme levels measured at day 49 for mice receiving AD-66810, AD-81890, or PBS are shown in Table 10 below. Figures 5A and 5B show ALT levels over time following administration of AD-66810 (Figure 5A) or AD-81890 (Figure 5B), relative to administration of PBS.

Table 10. Liver Enzyme Levels.

Group	dsRNA agent	Dose (mg/kg)	ALT (U/L)	AST (U/L)	ALP (U/L)	GTT (U/L)	TBIL (U/L)	TG (U/L)
1	AD-66810	12	391	261	407	17	0.3	102
2	AD-66810	36	505	293	398	22	0.2	85
3	AD-66810	100	611	338	392	26	0.3	83
4	AD-81890	12	293	210	375	13	0.3	95
5	AD-81890	36	267	198	376	11	0.3	112
6	AD-81890	100	330	237	410	14	0.2	103
7	PBS	0	139	146	329	10	0.2	110

For both test compound-treated groups, ALT, AST, ALP, and GGT showed an increase when compared with the control group. In addition, a dose-dependent change was demonstrated in ALT, AST, and GGT in the AD-66810-treated group.

In necropsy, there were no test compound-specific findings in either of the groups. When compared with the control group, there were no clear changes in relative (liver/body weight) liver weights of the animals in compound-treated groups.

## EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

10 While specific embodiments have been illustrated and described, it will be readily appreciated that the various embodiments described above can be combined to provide further embodiments, and that various changes can be made therein without departing from the spirit and scope of the invention.

15 All of the Figures, U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification or listed in the Application Data Sheet, including U.S. Provisional Patent application No. 62/718,314 filed August 13, 2018, are incorporated herein by reference, in their entirety, unless otherwise stated. Aspects of the 20 embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.

These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with 25 the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

## CLAIMS

We claim:

1. A double stranded ribonucleic acid (dsRNA) agent, comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises the modified nucleotide sequence as set forth in:

5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16),

5'-usGfsuga(Agn)gCGaaguGfdCAfcacsusu-3' (SEQ ID NO:18),

5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20),

5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23),

5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24),

5'-usGfsudGadAgdCGfaaguGfcAfdCacsusu-3' (SEQ ID NO:25), or

5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28),

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA); and

s is a phosphorothioate linkage.

2. The dsRNA agent of claim 1, wherein the sense strand comprises the modified nucleotide sequence 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29)

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively; and

s is a phosphorothioate linkage.

3. The dsRNA agent of claim 1, wherein the antisense strand and the sense strand comprise the modified nucleotide sequences as set forth in:

(a) 5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(b) 5'-usGfsuga(Agn)gCGaaguGfdCAfcacsusu-3' (SEQ ID NO:18) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(c) 5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(d) 5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(e) 5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

(f) 5'-usGfsudGadAgdCGfaaguGfcAfdCacsusu-3' (SEQ ID NO:25) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29); or

(g) 5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28) and 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO:29);

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA); and


s is a phosphorothioate linkage.

4. The dsRNA agent of any claims 1-3, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide.

5. The dsRNA agent of any one of claims 1-3, wherein at least one strand comprises a 3' overhang of 2 nucleotides.

6. The dsRNA agent of any one of claims 1-5, wherein the double stranded region is 19-21 nucleotide pairs in length.

7. The dsRNA agent of any one of claims 1-6, wherein each strand independently has 19-23 nucleotides.
8. The dsRNA agent of claim 7, where each strand independently has 19-21 nucleotides.
9. The dsRNA agent of any one of claims 1-8, further comprising a ligand.
10. The dsRNA agent of claim 9, wherein the ligand is conjugated to the 3' end of the sense strand of the dsRNA agent.
11. The dsRNA agent of claim 9 or 10, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.
12. The dsRNA agent of claim 11, wherein the ligand is





dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA); and  
s is a phosphorothioate linkage.

16. The dsRNA agent of claim 1, wherein the antisense strand and the sense strand consist of the modified nucleotide sequences as set forth in:

(a) 5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

(b) 5'-usGfsuga(Agn)gCGaaguGfdCAfcacsusu-3' (SEQ ID NO:18) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

(c) 5'-usGfsudGa(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:20) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

(d) 5'-usGfsudGadAgdCGfaaguGfcAfcacsusu-3' (SEQ ID NO:23) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

(e) 5'-usGfsuga(Agn)dGCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:24) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

(f) 5'-usGfsudGadAgdCGfaaguGfcAfdCacsusu-3' (SEQ ID NO:25) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10); or

(g) 5'-usGfsuga(Agn)gCfGfaaguGfdCAfcacsusu-3' (SEQ ID NO:28) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA);  
s is a phosphorothioate linkage; and

L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol.

17. The dsRNA agent of claim 1, wherein the antisense strand and the sense strand consist of the modified nucleotide sequences as set forth in:

5'-usGfsuga(Agn)gCfGfaaguGfcAfcacsusu-3' (SEQ ID NO:16) and 5'-gsusguGfcAfCfUfucgcuucacaL96-3' (SEQ ID NO:10);

wherein a, c, g, and u are 2'-O-methyladenosine-3'-phosphate, 2'-O-methylcytidine-3'-phosphate, 2'-O-methylguanosine-3'-phosphate, and 2'-O-methyluridine-3'-phosphate, respectively;

Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;

dA, dC, dG, and dT are 2'-deoxyadenosine-3'-phosphate, 2'-deoxycytidine-3'-phosphate, 2'-deoxyguanosine-3'-phosphate, and 2'-deoxythymidine-3'-phosphate, respectively;

(Agn) is adenosine-glycol nucleic acid (GNA);

s is a phosphorothioate linkage; and

L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl]-4-hydroxyprolinol.

18. The dsRNA agent of any one of claims 1-17, wherein the dsRNA agent inhibits expression of hepatitis B virus (HBV) in a cell.

19. A cell containing the dsRNA agent of any one of claims 1-18.

20. A pharmaceutical composition comprising the dsRNA agent of any one of claims 1-19 and a pharmaceutical excipient.

21. A method of inhibiting Hepatitis B virus (HBV) gene expression in a cell, the method comprising contacting the cell with the dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, thereby inhibiting expression of the HBV gene in the cell.

22. The method of claim 21, wherein the HBV gene expression is inhibited by at least 80%, 90%, 95%, or 98%, or to below the level of detection of the assay method.

23. A method of inhibiting replication of a Hepatitis B virus (HBV) in a cell, the method comprising contacting the cell with the dsRNA agent of any one of

claims 1-18, or a pharmaceutical composition of claim 20, thereby inhibiting replication of the HBV in the cell.

24. The method of claim 23, wherein replication of HBV in the cell is inhibited by at least 80%, 90%, 95%, or 98%, or to below the level of detection of the assay method.

25. The method of any one of claims 21-24, wherein the cell is within a subject.

26. The method of claim 25, wherein the subject is a human.

27. The method of claim 26, wherein the subject suffers from an HBV-associated disease.

28. The method of any one of claims 21-24, wherein the cell is *in vitro*.

29. A method of reducing the level of a Hepatitis B virus (HBV) antigen in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, thereby reducing the level of the HBV antigen in the subject.

30. The method of claim 29, wherein the HBV antigen is HBsAg.

31. The method of claim 29, wherein the HBV antigen is HBeAg.

32. The method of claim 29, wherein the antigen is measured in serum from the subject.

33. The method of claim 29, wherein the subject is HBeAg positive.

34. The method of claim 29, wherein the subject is HBeAg negative.

35. The method of any one of claims 29-34, wherein the HBV antigen level is reduced in serum by at least 1 log<sub>10</sub>, at least 2 log<sub>10</sub>, at least 3 log<sub>10</sub>, or at least 4 log<sub>10</sub>; or to below the level of detection of the assay.

36. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, thereby reducing the viral load of HBV in the subject.

37. The method of claim 36, wherein the HBV viral load is measured in serum from the subject.

38. The method of claim 36 or 37, wherein the subject is HBeAg positive.

39. The method of claim 36 or 37, wherein the subject is HBeAg negative.

40. The method of any one of claims 36-39, wherein the HBV viral load is reduced in serum by at least 1 log<sub>10</sub>, at least 2 log<sub>10</sub>, at least 3 log<sub>10</sub>, or at least 4 log<sub>10</sub>; or to below the level of detection of the assay.

41. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, thereby treating the subject.

42. A method of treating a subject having a Hepatitis B virus (HBV)-associated disorder, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, thereby treating the subject.

43. The method of claim 42, wherein the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive.

44. The method of claim 42, wherein the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative.

45. The method of any one of claims 21-44, wherein the dsRNA agent is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg, 0.5 mg/kg to 50 mg/kg, or 3 mg/kg to 10 mg/kg.

46. The method of claim 45, wherein the dsRNA agent is administered to the subject at a dose of 3 mg/kg to 10 mg/kg.

47. The method of any one of claims 21-44, wherein the dsRNA agent is administered to the subject at a fixed dose of 50 mg to 200 mg or 50 to 900 mg.

48. The method of any one of claims 21-47, wherein the dsRNA agent is administered to the subject subcutaneously.

49. The method of any one of claims 21-48, wherein the dsRNA agent is administered to the subject in two or more doses.

50. The method of any one of claims 21-49, wherein the dsRNA agent is administered to the subject once per month, once every two months, or once every three months.

51. The method of any one of claims 21-49, wherein the dsRNA agent is administered to the subject no more than once per month.

52. The method of any one of claims 21-51, further comprising administering to the subject one or more additional therapeutic agents.

53. The method of claim 52, wherein the additional therapeutic agent is an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion

or release of HbsAg, a capsid inhibitor, or a covalently closed circular (ccc) HBV DNA inhibitor, or a combination of any of the foregoing.

54. The method of claim 52, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.

55. The method of claim 52, wherein the additional therapeutic agents are a reverse transcriptase inhibitor and an immune stimulator.

56. The method of claim 54 or 55, wherein the reverse transcriptase inhibitor is Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, or AGX-1009.

57. The method of claim 55, wherein the immune stimulator is pegylated interferon alfa 2a (PEG-IFN- $\alpha$ 2a), Interferon alfa-2b, a recombinant human interleukin-7, or a Toll-like receptor 7 (TLR7) agonist.

58. A pharmaceutical composition for practicing any of the methods of any one of claims 21-57 comprising a dsRNA agent of any of claims 1-18 and a pharmaceutical excipient.

59. A dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, for use in the treatment of a Hepatitis B virus (HBV) infection in a subject.

60. A dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, for use in the treatment of a Hepatitis B virus (HBV)-associated disorder in a subject.

61. The dsRNA agent or pharmaceutical composition for use according to claim 60, wherein the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive.

62. The dsRNA agent or pharmaceutical composition for use according to claim 60, wherein the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative.

63. The dsRNA agent or pharmaceutical composition for use according to any one of claims 59-62, wherein the subject is being or has been administered one or more additional therapeutic agents.

64. The dsRNA agent or pharmaceutical composition for use according to claim 63, wherein the additional therapeutic agent is an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, or a covalently closed circular (ccc) HBV DNA inhibitor, or a combination of any of the foregoing.

65. The dsRNA agent or pharmaceutical composition for use according to claim 63, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.

66. The dsRNA agent or pharmaceutical composition for use according to claim 63, wherein the additional therapeutic agents are a reverse transcriptase inhibitor and an immune stimulator.


67. The dsRNA agent or pharmaceutical composition for use according to claim 65 or 66, wherein the reverse transcriptase inhibitor is Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, or AGX-1009.

68. The dsRNA agent or pharmaceutical composition for use according to claim 66, wherein the immune stimulator is pegylated interferon alfa 2a (PEG-IFN- $\alpha$ 2a), Interferon alfa-2b, a recombinant human interleukin-7, or a Toll-like receptor 7 (TLR7) agonist.

69. Use of a dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20 for practicing any of the methods of any one of claims 21-57.

70. Use of a dsRNA agent of any one of claims 1-18, or a pharmaceutical composition of claim 20, for the preparation of a medicament for practicing any of the methods of any one of claims 21-57.

1 / 4



**Fig. 1**

2 / 4




Fig. 2A






Fig. 2B

3 / 4




**Fig. 3**




**Fig. 4**

4 / 4



**Fig. 5A**



**Fig. 5B**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2019/046142

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
  - a.  forming part of the international application as filed:
    - in the form of an Annex C/ST.25 text file.
    - on paper or in the form of an image file.
  - b.  furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
  - c.  furnished subsequent to the international filing date for the purposes of international search only:
    - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
    - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2019/046142

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2019/046142

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C12N15/113 A61K31/713  
ADD. A61P31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, WPI Data, BIOSIS, COMPENDEX, EMBASE, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/077321 A1 (ALNYLAM PHARMACEUTICALS INC [US]) 19 May 2016 (2016-05-19) cited in the application X: second invention; claim 38; table 26; compounds AD-66810; sequence 1285	1-16, 18-70
X	WO 2017/027350 A2 (ARROWHEAD PHARMACEUTICALS INC [US]) 16 February 2017 (2017-02-16) X: second invention; page 21; compounds AM04661-AS; sequence 380	1-16, 18-70
	----- -/--	

Further documents are listed in the continuation of Box C.       See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  13 November 2019	Date of mailing of the international search report  22/11/2019
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Piret, Bernard

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2019/046142

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2018/027106 A2 (ARROWHEAD PHARMACEUTICALS INC [US]) 8 February 2018 (2018-02-08) X: second invention; page 104; compounds AM04661-AS; sequence 65</p>	1-16, 18-70
A	<p>----- MARK K. SCHLEGEL ET AL: "Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, no. 25, 19 June 2017 (2017-06-19), pages 8537-8546, XP055602525, US ISSN: 0002-7863, DOI: 10.1021/jacs.7b02694 -----</p>	1-70

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2019/046142

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016077321 A1	19-05-2016	AU 2015346513 A1	08-06-2017
		AU 2015346566 A1	08-06-2017
		BR 112017008868 A2	16-01-2018
		CA 2967408 A1	19-05-2016
		CN 108064293 A	22-05-2018
		CN 108064294 A	22-05-2018
		EA 201791014 A1	31-10-2017
		EP 3218487 A1	20-09-2017
		EP 3218489 A1	20-09-2017
		JP 2017534290 A	24-11-2017
		JP 2017538679 A	28-12-2017
		KR 20170077250 A	05-07-2017
		KR 20170077251 A	05-07-2017
		SG 11201703569X A	30-05-2017
		SG 11201703638X A	29-06-2017
		TW 201628659 A	16-08-2016
		TW 201631156 A	01-09-2016
		US 2017349900 A1	07-12-2017
		US 2017349901 A1	07-12-2017
		WO 2016077321 A1	19-05-2016
WO 2016077349 A1	19-05-2016		
-----			
WO 2017027350 A2	16-02-2017	AU 2016306275 A1	08-02-2018
		CA 2991639 A1	16-02-2017
		CN 108271387 A	10-07-2018
		EP 3332007 A2	13-06-2018
		JP 2018523668 A	23-08-2018
		KR 20180038465 A	16-04-2018
		US 2017035796 A1	09-02-2017
		US 2019022123 A1	24-01-2019
		WO 2017027350 A2	16-02-2017
		-----	
WO 2018027106 A2	08-02-2018	AU 2017306692 A1	21-02-2019
		BR 112019002117 A2	09-07-2019
		CA 3032945 A1	08-02-2018
		CN 109843902 A	04-06-2019
		CO 2019002017 A2	31-05-2019
		CR 20190056 A	20-05-2019
		EP 3494123 A2	12-06-2019
		JP 2019527694 A	03-10-2019
		KR 20190038606 A	08-04-2019
		PE 20190567 A1	22-04-2019
		PH 12019500245 A1	14-10-2019
		SG 11201900910T A	27-02-2019
		US 2019255091 A1	22-08-2019
		US 2019292547 A1	26-09-2019
		UY 37353 A	28-02-2018
		WO 2018027106 A2	08-02-2018
-----			

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-70

A double-stranded ribonucleic acid (dsRNA) agent wherein the antisense strand comprises the modified nucleotide sequence 5'-usGfsu(G)a(A)(G)(C)(G)aaguGf(C)Af(C)acsusu-3'; methods and products derived therefrom.

1.1. claims: 17(completely); 1-16, 18-70(partially)

A double-stranded ribonucleic acid (dsRNA) agent wherein the antisense strand comprises the modified nucleotide sequence 5'-usGfsu(G)a(A)(G)(C)(G)aaguGf(C)Af(C)acsusu-3' wherein the (A) residue at position 6 is an adenosine glycol nucleic acid (Agn) residue.

1.2. claims: 1-16, 18-70(all partially)

A double-stranded ribonucleic acid (dsRNA) agent wherein the antisense strand comprises the modified nucleotide sequence 5'-usGfsu(G)a(A)(G)(C)(G)aaguGf(C)Af(C)acsusu-3' wherein the (A) residue at position 6 is a deoxyadenosine (dA) residue.

---